{
  "letters": 698125,
  "pages": 186,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "Integra LifeSciences Holdings Corporation",
    "major_industry": "Healthcare",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 4,
          "title": "Business Overview and Strategic Acquisitions",
          "data": [
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Holdings Corporation"
            },
            {
              "key": "Acquisition Date",
              "value": "December 6, 2022"
            },
            {
              "key": "Acquired Entity",
              "value": "Surgical Innovation Associates, Inc."
            },
            {
              "key": "Acquired Product",
              "value": "DuraSorb®"
            },
            {
              "key": "Purpose of Acquisition",
              "value": "To advance global strategy in breast reconstruction"
            },
            {
              "key": "Previous Acquisition",
              "value": "ACell, Inc."
            },
            {
              "key": "Notes Reference",
              "value": "See Note 4, Acquisitions and Divestitures"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 5,
          "title": "Sale of Non-Core Businesses",
          "data": [
            {
              "key": "Transaction 1",
              "value": "Sale of traditional wound care business to Gentell, LLC for $28.8 million."
            },
            {
              "key": "Transaction 2",
              "value": "Sale of Extremity Orthopedics business to Smith & Nephew for approximately $240 million."
            },
            {
              "key": "Consideration Structure",
              "value": "Includes cash and contingent consideration based on revenue milestones."
            },
            {
              "key": "Date of Sale 1",
              "value": "August 2022"
            },
            {
              "key": "Date of Sale 2",
              "value": "January 2021"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 20,
          "title": "Merger and Acquisition Overview",
          "data": [
            {
              "key": "Acquisition Cost Total",
              "value": "$358.4 million"
            },
            {
              "key": "Acquisition 1",
              "value": "ACell, Inc."
            },
            {
              "key": "Acquisition 1 Cost",
              "value": "$306.9 million"
            },
            {
              "key": "Acquisition 2",
              "value": "Surgical Innovation Associates, Inc."
            },
            {
              "key": "Acquisition 2 Cost",
              "value": "$51.5 million"
            },
            {
              "key": "Growth Strategy",
              "value": "Growth through acquisitions"
            },
            {
              "key": "Risks of Acquisitions",
              "value": "Significant transaction expenses, integration challenges, and potential liabilities"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 33,
          "title": "Merger and Acquisition Overview",
          "data": [
            {
              "key": "Company",
              "value": "Integra LifeSciences Holdings Corporation"
            },
            {
              "key": "Acquisition Date",
              "value": "December 6, 2022"
            },
            {
              "key": "Acquired Company",
              "value": "SIA"
            },
            {
              "key": "Product",
              "value": "DuraSorb"
            },
            {
              "key": "Application",
              "value": "Plastic and reconstructive surgery"
            },
            {
              "key": "Strategic Importance",
              "value": "Advancing Integra’s global strategy in breast reconstruction"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 36,
          "title": "Acquisitions & Divestitures",
          "data": [
            {
              "key": "Acquisition of Surgical Innovation Associates, Inc.",
              "value": "On December 6, 2022, the Company completed its acquisition for an acquisition purchase price of $51.5 million, including contingent payments based on revenue performance milestones and FDA approval."
            },
            {
              "key": "Acquisition of ACell Inc.",
              "value": "On January 20, 2021, the Company acquired ACell for an acquisition purchase price of $306.9 million plus up to $100 million in contingent consideration based on performance milestones."
            },
            {
              "key": "Sale of TWC business",
              "value": "On August 31, 2022, the Company completed the sale to Gentell for $28.8 million, including contingent consideration based on performance milestones."
            },
            {
              "key": "Sale of Extremity Orthopedics business",
              "value": "On January 4, 2021, the Company sold its business to Smith & Nephew for $240.0 million."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 37,
          "title": "OPTIMIZATION AND INTEGRATION ACTIVITIES",
          "data": [
            {
              "key": "Net Income 2022",
              "value": "$180.6 million"
            },
            {
              "key": "Net Income 2021",
              "value": "$169.1 million"
            },
            {
              "key": "Acquisition, divestiture and integration-related charges 2022",
              "value": "$-18.8 million"
            },
            {
              "key": "Acquisition, divestiture and integration-related charges 2021",
              "value": "$-11.7 million"
            },
            {
              "key": "Structural optimization charges 2022",
              "value": "$23.1 million"
            },
            {
              "key": "Structural optimization charges 2021",
              "value": "$20.8 million"
            },
            {
              "key": "EU medical device regulation 2022",
              "value": "$45.1 million"
            },
            {
              "key": "EU medical device regulation 2021",
              "value": "$24.4 million"
            },
            {
              "key": "Total charges 2022",
              "value": "$49.4 million"
            },
            {
              "key": "Total charges 2021",
              "value": "$33.4 million"
            },
            {
              "key": "Total expenses 2022",
              "value": "$49.4 million"
            },
            {
              "key": "Total expenses 2021",
              "value": "$33.4 million"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 44,
          "title": "Acquisitions",
          "data": [
            {
              "key": "Valuation Methodology",
              "value": "Business combinations are accounted for in accordance with ASC Topic 805. Fair values at the date of acquisition are determined for assets acquired and liabilities assumed."
            },
            {
              "key": "Goodwill Recognition",
              "value": "Any excess of the purchase price over the fair value of net assets acquired is recorded as goodwill."
            },
            {
              "key": "Contingent Consideration",
              "value": "Contingent consideration is recorded at fair value at the acquisition date, based on future financial projections."
            },
            {
              "key": "Transaction Costs",
              "value": "Transaction costs and restructuring costs are expensed as incurred."
            },
            {
              "key": "Estimates and Assumptions",
              "value": "Valuations require significant judgment related to future cash flows, discount rates, and the life cycle of intangible assets."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 51,
          "title": "Exhibits required to be filed by Item 601 of Regulation S-K",
          "data": [
            {
              "key": "exhibit_number",
              "value": "2.1(a)"
            },
            {
              "key": "description",
              "value": "Put Option Agreement, dated September 29, 2020, between the Company and certain of its subsidiaries and Smith & Nephew USD Limited"
            },
            {
              "key": "exhibit_number",
              "value": "2.1(b)"
            },
            {
              "key": "description",
              "value": "Agreement and Plan of Merger by among Integra LifeSciences Holdings Corporation and ACell Inc. dated as of December 15, 2020"
            },
            {
              "key": "exhibit_number",
              "value": "3.1(a)"
            },
            {
              "key": "description",
              "value": "Amended and Restated Certificate of Incorporation of the Company dated February 16, 1993"
            },
            {
              "key": "exhibit_number",
              "value": "3.1(b)"
            },
            {
              "key": "description",
              "value": "Certificate of Amendment to Amended and Restated Certificate of Incorporation dated May 22, 1998"
            },
            {
              "key": "exhibit_number",
              "value": "3.2"
            },
            {
              "key": "description",
              "value": "Second Amended and Restated Bylaws of Integra LifeSciences Holdings Corporation, effective December 11, 2018"
            },
            {
              "key": "exhibit_number",
              "value": "4.1"
            },
            {
              "key": "description",
              "value": "Indenture, dated February 7, 2020, between Integra LifeSciences Holdings Corporation and Citibank, N.A."
            },
            {
              "key": "exhibit_number",
              "value": "4.4"
            },
            {
              "key": "description",
              "value": "Description of Securities"
            },
            {
              "key": "exhibit_number",
              "value": "10.1(a)"
            },
            {
              "key": "description",
              "value": "Lease Modification #3 entered into as of March 2, 2011, between Plainsboro Associates and Integra LifeSciences Corporation"
            },
            {
              "key": "exhibit_number",
              "value": "10.1(b)"
            },
            {
              "key": "description",
              "value": "Lease Modification #4 entered into as of April 20, 2017, between Plainsboro Associates and Integra LifeSciences Corporation"
            },
            {
              "key": "exhibit_number",
              "value": "10.2(a)"
            },
            {
              "key": "description",
              "value": "Employee Stock Purchase Plan (as amended on May 17, 2004)"
            },
            {
              "key": "exhibit_number",
              "value": "10.2(b)"
            },
            {
              "key": "description",
              "value": "First Amendment to Employee Stock Purchase Plan, dated October 26, 2005"
            },
            {
              "key": "exhibit_number",
              "value": "10.3(a)"
            },
            {
              "key": "description",
              "value": "Second Amended and Restated 2003 Equity Incentive Plan effective May 19, 2010"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 59,
          "title": "Surgical Innovation Associates, Inc. Acquisition - Valuation of Developed Technology Intangible Asset",
          "data": [
            {
              "key": "Acquisition Date",
              "value": "December 6, 2022"
            },
            {
              "key": "Acquisition Purchase Price",
              "value": "$51.5 million"
            },
            {
              "key": "Additional Payments",
              "value": "up to $50 million upon revenue-based performance milestones in 2023, 2024, and 2025"
            },
            {
              "key": "FDA Approval Payment",
              "value": "up to $40 million upon FDA approval of Premarketing Approval Application for DuraSorb"
            },
            {
              "key": "Developed Technology Intangible Asset Recorded",
              "value": "$75 million"
            },
            {
              "key": "Valuation Method",
              "value": "multi-period excess earnings method of the income approach"
            },
            {
              "key": "Audit Firm",
              "value": "PricewaterhouseCoopers LLP"
            },
            {
              "key": "Audit Opinion Date",
              "value": "February 22, 2023"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 76,
          "title": "Surgical Innovation Associates, Inc. Acquisition",
          "data": [
            {
              "key": "Acquisition Date",
              "value": "December 6, 2022"
            },
            {
              "key": "Acquisition Purchase Price",
              "value": "$51.5 million"
            },
            {
              "key": "Additional Payments based on Performance Milestones",
              "value": "up to $50.0 million"
            },
            {
              "key": "Additional Payments based on FDA Approval",
              "value": "up to $40.0 million"
            },
            {
              "key": "Product",
              "value": "DuraSorb"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 77,
          "title": "Assets and Liabilities Valuation Statement",
          "data": [
            {
              "key": "Total assets",
              "value": "$127,397,000"
            },
            {
              "key": "Intangible assets",
              "value": "$75,000,000"
            },
            {
              "key": "Goodwill",
              "value": "$41,854,000"
            },
            {
              "key": "Total liabilities",
              "value": "$71,450,000"
            },
            {
              "key": "Net assets acquired",
              "value": "$55,947,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 78,
          "title": "Sale of non-core traditional wound care business",
          "data": [
            {
              "key": "Sale Date",
              "value": "August 31, 2022"
            },
            {
              "key": "Buyer",
              "value": "Gentell, LLC"
            },
            {
              "key": "Sale Amount",
              "value": "$28.8 million"
            },
            {
              "key": "Sale Cash Component",
              "value": "$27.8 million"
            },
            {
              "key": "Contingent Consideration",
              "value": "$1.0 million"
            },
            {
              "key": "Business Sold",
              "value": "traditional wound care (TWC) business"
            },
            {
              "key": "Gain from Sale",
              "value": "$0.6 million"
            },
            {
              "key": "Date of Extremity Orthopedics Sale",
              "value": "January 4, 2021"
            },
            {
              "key": "Buyer for Extremity Orthopedics",
              "value": "Smith & Nephew USD Limited"
            },
            {
              "key": "Purchase Price for Extremity Orthopedics",
              "value": "$240.0 million"
            },
            {
              "key": "Payment to CFO",
              "value": "$41.5 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 79,
          "title": "Assets and Liabilities Held for Sale",
          "data": [
            {
              "key": "Prepaid expenses and other current assets",
              "value": "713"
            },
            {
              "key": "Right of use asset - operating leases and Other assets",
              "value": "3186"
            },
            {
              "key": "Deferred tax assets",
              "value": "6589"
            },
            {
              "key": "Intangible assets, net",
              "value": "13332"
            },
            {
              "key": "Property, plant and equipment, net",
              "value": "37893"
            },
            {
              "key": "Goodwill",
              "value": "47546"
            },
            {
              "key": "Inventories",
              "value": "52845"
            },
            {
              "key": "Total assets held for sale",
              "value": "162104"
            },
            {
              "key": "Other liabilities",
              "value": "null"
            },
            {
              "key": "Current portion of lease liability - operating leases",
              "value": "null"
            },
            {
              "key": "Accrued compensation",
              "value": "null"
            },
            {
              "key": "Deferred tax liabilities",
              "value": "null"
            },
            {
              "key": "Lease liability - operating leases",
              "value": "null"
            },
            {
              "key": "Total liabilities held for sale",
              "value": "null"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 80,
          "title": "Assets and Liabilities Acquired",
          "data": [
            {
              "key": "Total assets acquired",
              "value": "408780"
            },
            {
              "key": "Total liabilities assumed",
              "value": "101842"
            },
            {
              "key": "Net assets acquired",
              "value": "306938"
            },
            {
              "key": "Intangible assets fair value",
              "value": "245000"
            },
            {
              "key": "Goodwill recognized",
              "value": "94147"
            },
            {
              "key": "Deferred tax liability",
              "value": "61724"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 81,
          "title": "Contingent Consideration and Debt Amendment",
          "data": [
            {
              "key": "Acquisition Details",
              "value": "As part of the acquisition, the Company is required to make payments to the former shareholders of ACell up to $100 million based on the achievement of certain revenue-based performance milestones in 2022, 2023, and 2025."
            },
            {
              "key": "Estimated Fair Value of Contingent Consideration",
              "value": "$23.9 million at the acquisition date."
            },
            {
              "key": "Recorded Other Liabilities (2022)",
              "value": "$3.7 million as of December 31, 2022."
            },
            {
              "key": "Recorded Other Liabilities (2021)",
              "value": "$21.8 million as of December 31, 2021."
            },
            {
              "key": "Debt Amendment Date",
              "value": "February 3, 2020."
            },
            {
              "key": "Credit Facility Maturity Date",
              "value": "February 3, 2025."
            },
            {
              "key": "Aggregate Principal Amount Available",
              "value": "Up to approximately $2.2 billion."
            },
            {
              "key": "Term Loan Facility Amount",
              "value": "$877.5 million."
            },
            {
              "key": "Revolving Credit Facility Amount",
              "value": "$1.3 billion."
            },
            {
              "key": "Interest Rates on Borrowings",
              "value": "ranging from 1.00% to 2.25%."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 103,
          "title": "Contingent Consideration Liabilities Movement - Year ended December 31, 2022",
          "data": [
            {
              "key": "Balance as of January 1, 2022",
              "value": "Short-term: 3691, Long-term: 11408"
            },
            {
              "key": "Additions",
              "value": "Short-term: 0, Long-term: 0, SIA Long-term: 57607"
            },
            {
              "key": "Transfers from long-term to current portion",
              "value": "Short-term: 4885 from ACell, Long-term: -4885 from ACell"
            },
            {
              "key": "Change in fair value of contingent consideration liabilities",
              "value": "Short-term: -846 from Arkis, Long-term: -1358 from Arkis"
            },
            {
              "key": "Balance as of December 31, 2022",
              "value": "Short-term: 2845 from Arkis, Long-term: 10050 from Arkis, Long-term: 57607 from SIA"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 125,
          "title": "Bylaws Overview and Stock Management",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Uncertificated Shares",
              "value": "The board of directors may provide that some or all classes or series of its stock shall be uncertificated shares."
            },
            {
              "key": "Lost Certificates Procedure",
              "value": "A new certificate may be issued upon affidavit of the loss, with possible requirements for advertisement and bond."
            },
            {
              "key": "Transfer of Stock",
              "value": "Upon proper surrender of certificate, a new certificate shall be issued and the transaction recorded."
            },
            {
              "key": "Record Date Fixing",
              "value": "The Board of Directors may fix a record date for determining stockholders entitled to corporate actions, not less than 10 nor more than 60 days prior to the event."
            },
            {
              "key": "Registered Stockholders Rights",
              "value": "The Corporation recognizes registered stockholders as the exclusive owners for dividends and voting."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 178,
          "title": "Subsidiaries of Integra LifeSciences Holdings Corporation",
          "data": [
            {
              "key": "Number of Subsidiaries",
              "value": "32"
            },
            {
              "key": "Common Incorporation Location",
              "value": "Delaware (12 subsidiaries)"
            },
            {
              "key": "Other Countries",
              "value": "United Kingdom (3 subsidiaries), Germany (3 subsidiaries), Canada, Ireland, Switzerland, Japan"
            },
            {
              "key": "Sector",
              "value": "Medical and life sciences, Surgical products, Biosciences, Medical technologies"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 179,
          "title": "Global Subsidiaries and Affiliates of Integra LifeSciences Corporation",
          "data": [
            {
              "key": "Company Name",
              "value": "Integra LifeSciences (Shanghai) Co., Ltd."
            },
            {
              "key": "Location",
              "value": "China"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Austria GmbH"
            },
            {
              "key": "Location",
              "value": "Austria"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Brazil Ltda."
            },
            {
              "key": "Location",
              "value": "Brazil"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Corporation"
            },
            {
              "key": "Location",
              "value": "Delaware"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Enterprises, LLLP"
            },
            {
              "key": "Location",
              "value": "Delaware"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Financing (Cyprus) Limited"
            },
            {
              "key": "Location",
              "value": "Cyprus"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Italy S.r.l."
            },
            {
              "key": "Location",
              "value": "Italy"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Korea Ltd."
            },
            {
              "key": "Location",
              "value": "Korea"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Middle East FZ-LLC"
            },
            {
              "key": "Location",
              "value": "Dubai"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Production Corporation"
            },
            {
              "key": "Location",
              "value": "Delaware"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Sales LLC"
            },
            {
              "key": "Location",
              "value": "Delaware"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Services (France) SAS"
            },
            {
              "key": "Location",
              "value": "France"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Shared Services (Ireland) Limited"
            },
            {
              "key": "Location",
              "value": "Ireland"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Singapore Pte. Ltd."
            },
            {
              "key": "Location",
              "value": "Singapore"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Spain, S.L."
            },
            {
              "key": "Location",
              "value": "Spain"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Switzerland Sarl"
            },
            {
              "key": "Location",
              "value": "Switzerland"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Taiwan Company Limited"
            },
            {
              "key": "Location",
              "value": "Taiwan"
            },
            {
              "key": "Company Name",
              "value": "Integra LS (Benelux) NV"
            },
            {
              "key": "Location",
              "value": "Belgium"
            },
            {
              "key": "Company Name",
              "value": "Integra LS Mexico, S. DE R. L. DEC.V."
            },
            {
              "key": "Location",
              "value": "Mexico"
            },
            {
              "key": "Company Name",
              "value": "Integra Luxtec, Inc."
            },
            {
              "key": "Location",
              "value": "Massachusetts"
            },
            {
              "key": "Company Name",
              "value": "Integra ME GmbH"
            },
            {
              "key": "Location",
              "value": "Germany"
            },
            {
              "key": "Company Name",
              "value": "Integra MicroFrance SAS"
            },
            {
              "key": "Location",
              "value": "France"
            },
            {
              "key": "Company Name",
              "value": "Integra NeuroSciences (International), Inc."
            },
            {
              "key": "Location",
              "value": "Delaware"
            },
            {
              "key": "Company Name",
              "value": "Integra NeuroSciences Holdings (UK) Limited"
            },
            {
              "key": "Location",
              "value": "United Kingdom"
            },
            {
              "key": "Company Name",
              "value": "Integra NeuroSciences Holdings B.V."
            },
            {
              "key": "Location",
              "value": "Netherlands"
            },
            {
              "key": "Company Name",
              "value": "Integra NeuroSciences Implants (France) SAS"
            },
            {
              "key": "Location",
              "value": "France"
            },
            {
              "key": "Company Name",
              "value": "Integra NeuroSciences Limited"
            },
            {
              "key": "Location",
              "value": "United Kingdom"
            },
            {
              "key": "Company Name",
              "value": "Integra Neurosciences Pty Ltd. (AUS)"
            },
            {
              "key": "Location",
              "value": "Australia"
            },
            {
              "key": "Company Name",
              "value": "Integra Neurosciences Pty Ltd. (NZ)"
            },
            {
              "key": "Location",
              "value": "New Zealand"
            },
            {
              "key": "Company Name",
              "value": "Integra Receivables LLC"
            },
            {
              "key": "Location",
              "value": "Delaware"
            },
            {
              "key": "Company Name",
              "value": "Integra Sales, Inc."
            },
            {
              "key": "Location",
              "value": "Delaware"
            },
            {
              "key": "Company Name",
              "value": "Integra Selector LLC"
            },
            {
              "key": "Location",
              "value": "Delaware"
            },
            {
              "key": "Company Name",
              "value": "Integra Switzerland Holdings Sarl"
            },
            {
              "key": "Location",
              "value": "Switzerland"
            },
            {
              "key": "Company Name",
              "value": "Integra York PA, Inc."
            },
            {
              "key": "Location",
              "value": "Delaware"
            },
            {
              "key": "Company Name",
              "value": "IsoTis NV"
            },
            {
              "key": "Location",
              "value": "Netherlands"
            },
            {
              "key": "Company Name",
              "value": "IsoTis T.E. Facility B.V."
            },
            {
              "key": "Location",
              "value": "Netherlands"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 1,
          "title": "Company Registration Information",
          "data": [
            {
              "key": "(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)",
              "value": ""
            },
            {
              "key": "(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)",
              "value": "Delaware"
            },
            {
              "key": "(I.R.S. EMPLOYER IDENTIFICATION NO.)",
              "value": "51-0317849"
            },
            {
              "key": "ADDRESS OF PRINCIPAL EXECUTIVE OFFICES",
              "value": "1100 Campus Road, Princeton, New Jersey"
            },
            {
              "key": "ZIP CODE",
              "value": "08540"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 1,
          "title": "Securities Registration Information",
          "data": [
            {
              "key": "Title of Each",
              "value": ""
            },
            {
              "key": "Class",
              "value": ""
            },
            {
              "key": "Trading Symbol",
              "value": ""
            },
            {
              "key": "Name of",
              "value": ""
            },
            {
              "key": "Exchange on Which",
              "value": ""
            },
            {
              "key": "Registered",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 2,
          "title": "Company Filing Classifications",
          "data": [
            {
              "key": "Filer Status",
              "value": "Non-accelerated filer"
            },
            {
              "key": "Type",
              "value": "Smaller"
            },
            {
              "key": "Company Classification",
              "value": "Merging growth company"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 3,
          "title": "Form 10-K Table of Contents",
          "data": [
            {
              "key": "Summary",
              "value": "This table represents the standard table of contents from a Form 10-K filing, which is an annual report required by the SEC for publicly traded companies. The content is organized into four parts and includes 16 main items covering various aspects of business operations, financial statements, risk factors, corporate governance, and other regulatory disclosures. The table provides a comprehensive overview of the document's structure and the mandatory reporting requirements for public companies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 15,
          "title": "Gender Distribution Across Leadership Levels",
          "data": [
            {
              "key": "All Employees",
              "value": "52% Male, 48% Female"
            },
            {
              "key": "Executive Leadership",
              "value": "62% Male, 38% Female"
            },
            {
              "key": "Senior Leadership",
              "value": "57% Male, 43% Female"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 56,
          "title": "Signatures",
          "data": [
            {
              "key": "Company",
              "value": "INTEGRA LIFESCIENCES HOLDINGS CORPORATION"
            },
            {
              "key": "Executive",
              "value": "Jan De Witte"
            },
            {
              "key": "Title",
              "value": "President and Chief Executive Officer (Principal Executive Officer)"
            },
            {
              "key": "Executive",
              "value": "Jeffrey A. Mosebrook"
            },
            {
              "key": "Title",
              "value": "Senior Vice President, Finance (Principal Financial Officer and Principal Accounting Officer)"
            },
            {
              "key": "Date",
              "value": "February 22, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 57,
          "title": "Board Signatures and Appointments",
          "data": [
            {
              "key": "signature",
              "value": "Jan De Witte"
            },
            {
              "key": "title",
              "value": "President and Chief Executive Officer, and Director (Principal Executive Officer)"
            },
            {
              "key": "date",
              "value": "February 22, 2023"
            },
            {
              "key": "signature",
              "value": "Jeffrey A. Mosebrook"
            },
            {
              "key": "title",
              "value": "Senior Vice President, Finance (Principal Financial Officer and Principal Accounting Officer)"
            },
            {
              "key": "date",
              "value": "February 22, 2023"
            },
            {
              "key": "signature",
              "value": "Stuart M. Essig, Ph.D."
            },
            {
              "key": "title",
              "value": "Chairman of the Board"
            },
            {
              "key": "date",
              "value": "February 22, 2023"
            },
            {
              "key": "signature",
              "value": "Keith Bradley, Ph.D."
            },
            {
              "key": "title",
              "value": "Director"
            },
            {
              "key": "date",
              "value": "February 22, 2023"
            },
            {
              "key": "signature",
              "value": "Shaundra Clay"
            },
            {
              "key": "title",
              "value": "Director"
            },
            {
              "key": "date",
              "value": "February 22, 2023"
            },
            {
              "key": "signature",
              "value": "Barbara B. Hill"
            },
            {
              "key": "title",
              "value": "Director"
            },
            {
              "key": "date",
              "value": "February 22, 2023"
            },
            {
              "key": "signature",
              "value": "Renee Lo"
            },
            {
              "key": "title",
              "value": "Director"
            },
            {
              "key": "date",
              "value": "February 22, 2023"
            },
            {
              "key": "signature",
              "value": "Donald E. Morel, Jr., Ph.D."
            },
            {
              "key": "title",
              "value": "Director"
            },
            {
              "key": "date",
              "value": "February 22, 2023"
            },
            {
              "key": "signature",
              "value": "Raymond G. Murphy"
            },
            {
              "key": "title",
              "value": "Director"
            },
            {
              "key": "date",
              "value": "February 22, 2023"
            },
            {
              "key": "signature",
              "value": "Christian S. Schade"
            },
            {
              "key": "title",
              "value": "Director"
            },
            {
              "key": "date",
              "value": "February 22, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 106,
          "title": "Third Amended and Restated Bylaws of Integra Lifesciences Holdings Corporation",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Offices",
              "value": "The Corporation may have offices within and outside the State of Delaware."
            },
            {
              "key": "Annual Meeting Schedule",
              "value": "The annual meeting shall be held at nine o’clock A.M. on the first Monday of May."
            },
            {
              "key": "Business to be Conducted at Meeting",
              "value": "Business must be specified in the notice of meeting or properly brought by stockholders."
            },
            {
              "key": "Eligibility to Propose Business",
              "value": "Only stockholders of record entitled to vote may propose business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 107,
          "title": "Nominations for Election to the Board",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Notice Requirement",
              "value": "Timely Notice must be given between ninety (90) to one hundred twenty (120) days prior to the annual meeting."
            },
            {
              "key": "Stockholder Information",
              "value": "Includes name, address, class or series, number of shares owned."
            },
            {
              "key": "Synthetic Equity Interests",
              "value": "Must disclose any derivatives or transactions giving economic risk similar to ownership."
            },
            {
              "key": "Voting Rights",
              "value": "Any agreements related to voting rights must be disclosed."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 109,
          "title": "Proposing Person Notice Requirements",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Requirements for Proposing Persons",
              "value": "Identification of names and addresses of stockholders supporting nominations."
            },
            {
              "key": "Voting Rights Statement",
              "value": "Representation that the stockholder intends to vote at the meeting."
            },
            {
              "key": "Proxy Statement Delivery",
              "value": "To holders of the necessary voting power for approval."
            },
            {
              "key": "Currency",
              "value": "N/A"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 111,
          "title": "Bylaws and Shareholder Meetings Overview",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Disclosure Requirements",
              "value": "Corporation not obligated to disclose information regarding director nominees."
            },
            {
              "key": "Public Disclosure",
              "value": "Defined as disclosure in press releases or SEC filings."
            },
            {
              "key": "Notice of Meetings",
              "value": "Notice to stockholders required to be given 10-60 days before meetings."
            },
            {
              "key": "Adjournment of Meetings",
              "value": "No new notice required if adjourned meeting announcements are made."
            },
            {
              "key": "List of Stockholders",
              "value": "Complete list to be prepared 10 days before meetings."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 112,
          "title": "Section 2.06 Inspector of Election and Meeting Procedures",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Responsibilities of Inspectors",
              "value": "Appoint an inspector of election prior to any meeting of stockholders, with duties as set forth in Section 231 of DGCL."
            },
            {
              "key": "Special Meetings",
              "value": "May be called by the Chairman, the President, or the Board of Directors."
            },
            {
              "key": "Quorum Requirements",
              "value": "A majority of the stock issued and outstanding present constitutes a quorum."
            },
            {
              "key": "Voting Method",
              "value": "Stockholders entitled to one vote per share, method for electronic voting can be established by the Board."
            },
            {
              "key": "Proxy Solicitation",
              "value": "Must use a distinct color proxy card, not white reserved for Board use."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 113,
          "title": "Section on Written Consent for Corporate Actions",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Requirement for Action",
              "value": "Written consent from stockholders required"
            },
            {
              "key": "Inspection of Consents",
              "value": "Independent inspectors of elections must review validity of consents"
            },
            {
              "key": "Record Date",
              "value": "Fixed by the Board of Directors upon request from stockholders"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 114,
          "title": "Procedures for Nominations to the Board of Directors",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Section",
              "value": "2.09"
            },
            {
              "key": "Note",
              "value": "Board of Directors shall not be required to fix a record date if requests are not compliant."
            },
            {
              "key": "Nominations",
              "value": "Made at annual/special meetings by Board direction or eligible stockholders."
            },
            {
              "key": "Eligibility Requirements",
              "value": "Stockholder must provide timely written notice to the Secretary."
            },
            {
              "key": "Timely Notice",
              "value": "Must be provided 120 days prior to special meeting and no later than 90 days prior."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 115,
          "title": "Nominee Information and Election of Directors",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Nominating Person Definitions",
              "value": "Substitution of term to Nominating Person in Section 2.03(c)(ii)"
            },
            {
              "key": "Required Information for Nominees",
              "value": "Background and qualifications questionnaire, representation and agreement regarding Voting Commitments, compliance with corporation policies, intention to serve, irrevocable resignation condition, additional requested information"
            },
            {
              "key": "Proxy Statement Requirements",
              "value": "Consent to be named in proxy statement, disclosures required under Exchange Act Section 14(a)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 116,
          "title": "Nominating Procedures for Director Elections",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Nominating Person Definition",
              "value": "Stockholder providing notice, beneficial owner, affiliate or associate."
            },
            {
              "key": "Update Requirements",
              "value": "Update notice of nomination with correct information as of the record date and up to ten business days prior to the meeting."
            },
            {
              "key": "Secretary Notification",
              "value": "Written notice to Secretary required by Nominating Person regarding proxy solicitation status."
            },
            {
              "key": "Eligibility for Election",
              "value": "No person shall be eligible for election unless nominated according to these provisions."
            },
            {
              "key": "Determination of Compliance",
              "value": "Board of Directors or designated committee to determine if nominations were made according to Bylaws."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 117,
          "title": "Nominating Procedure for Director Nominees",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Key Provision",
              "value": "Nominating Person must be a qualified representative to present a nomination."
            },
            {
              "key": "Proxy Requirements",
              "value": "Proxy must be authorized in writing or electronic transmission."
            },
            {
              "key": "Compliance Requirements",
              "value": "Nominating Person must comply with Rules 14a-19 under the Exchange Act."
            },
            {
              "key": "Nomination Disqualification",
              "value": "Failure to comply may lead to disqualification of nomination."
            },
            {
              "key": "Meeting Procedure",
              "value": "Chairman or President to preside over stockholder meetings."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 118,
          "title": "Meeting Proceedings and Directors' Election",
          "data": [
            {
              "key": "effective_date",
              "value": "February 21, 2023"
            },
            {
              "key": "chairman",
              "value": "Chairman of the meeting"
            },
            {
              "key": "directors_minimum",
              "value": "3"
            },
            {
              "key": "directors_maximum",
              "value": "13"
            },
            {
              "key": "election_method",
              "value": "majority vote unless more nominees than positions"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 119,
          "title": "Corporate Governance Procedures for the Board of Directors",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Board of Directors Action",
              "value": "Will act on recommendation from Corporate Governance Committee within 90 days"
            },
            {
              "key": "Director Resignation Policy",
              "value": "Directors may resign at any time by giving written notice"
            },
            {
              "key": "Management Direction",
              "value": "Managed under the direction of its Board of Directors"
            },
            {
              "key": "Meeting Location",
              "value": "May hold meetings within or without the State of Delaware"
            },
            {
              "key": "Annual Meeting Purpose",
              "value": "Organization, election of officers, transaction of business"
            },
            {
              "key": "Regular Meetings",
              "value": "May be held without notice at determined time and place"
            },
            {
              "key": "Special Meetings Notice",
              "value": "Called by the Chairman or President on 2 days’ notice"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 120,
          "title": "Compensation of Directors",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Quorum Requirement",
              "value": "Majority of directors"
            },
            {
              "key": "Voting Requirement",
              "value": "Act of a majority of directors present"
            },
            {
              "key": "Action Without Meeting",
              "value": "Consent in writing or electronic transmission"
            },
            {
              "key": "Telephonic Meeting Permitted",
              "value": "Allowed with conference telephone or communications equipment"
            },
            {
              "key": "Committees of Directors",
              "value": "Designated by majority resolution of the Board"
            },
            {
              "key": "Compensation of Directors",
              "value": "As fixed by the Board; reimbursement for reasonable expenses"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 121,
          "title": "Leadership and Responsibilities of the Board of Directors",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Presiding Director",
              "value": "The Board of Directors may appoint a presiding director for a term not exceeding one year."
            },
            {
              "key": "Qualifications and Duties",
              "value": "Determined by the Board of Directors, including presiding over meetings if the Chairman is absent."
            },
            {
              "key": "Officers",
              "value": "The officers of the Corporation shall be a Chairman of the Board, a Chief Executive Officer, a President, a Chief Financial Officer, a Secretary and a Treasurer, and may include Vice Presidents, Assistant Secretaries, and Assistant Treasurers."
            },
            {
              "key": "Election and Term of Office",
              "value": "Officers shall be elected by the Board and hold office at its pleasure."
            },
            {
              "key": "Removal",
              "value": "Any officer may be removed at any time by the Board with or without cause."
            },
            {
              "key": "Chairman Duties",
              "value": "The Chairman shall preside at all meetings and perform additional duties as assigned by the Board."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 122,
          "title": "Leadership Structure of the Corporation",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Chief Executive Officer",
              "value": "Overall responsibility for management and operations"
            },
            {
              "key": "Chief Financial Officer",
              "value": "General responsibility for financial affairs"
            },
            {
              "key": "President",
              "value": "Acts in absence of CEO; manages operations"
            },
            {
              "key": "Executive Vice Presidents",
              "value": "Managerial duties as specified; succeed President if absent"
            },
            {
              "key": "Vice Presidents",
              "value": "Duties as specified by governance documents"
            },
            {
              "key": "Secretary",
              "value": "Attends meetings and records proceedings, manages corporate seal"
            },
            {
              "key": "Assistant Secretaries",
              "value": "Perform duties of Secretary in their absence"
            },
            {
              "key": "Treasurer",
              "value": "Custody of corporate funds and accounts"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 124,
          "title": "Indemnification and Advancement of Expenses",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Description",
              "value": "The Corporation's indemnification policy for directors and officers and the rights of indemnification are outlined."
            },
            {
              "key": "Insurance Provision",
              "value": "The Corporation may purchase insurance for directors, officers, and employees against liabilities."
            },
            {
              "key": "Contractual Rights",
              "value": "The rights conferred under the indemnification article are contractual and fully vested upon commencement of service."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 129,
          "title": "Advances Notice Requirements and Forum Selection",
          "data": [
            {
              "key": "Advance Notice Requirements",
              "value": "Provisions requiring advance notice for stockholder proposals and director nominations."
            },
            {
              "key": "Director Appointment",
              "value": "A director appointed to fill a vacancy serves the remainder of the term."
            },
            {
              "key": "Amendment of Bylaws",
              "value": "Stockholders can adopt, amend or repeal bylaws with board approval."
            },
            {
              "key": "Forum Selection",
              "value": "Bylaws provide sole forum for certain actions in Delaware."
            },
            {
              "key": "Preferred Stock Issuance",
              "value": "Board can issue preferred stock without stockholder approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 147,
          "title": "Electronic Signature Authorization Form",
          "data": [
            {
              "key": "signature_requirement",
              "value": "[THE PARTICIPANT :lectronic signature to be provided ind recorded via online grant acceptance process on www.etrade.com"
            },
            {
              "key": "company_details",
              "value": "INTEGRA LIFESCIENCES HOLDINGS CORPORATION"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 147,
          "title": "Electronic Signature Authorization Form",
          "data": [
            {
              "key": "signature_requirement",
              "value": ""
            },
            {
              "key": "company_details",
              "value": "By. Name: Title:"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 165,
          "title": "Award Agreement Details",
          "data": [
            {
              "key": "Participant",
              "value": "Integra Lifesciences Holdings Corporation"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 173,
          "title": "Award Agreement Acknowledgment and Reporting Obligations",
          "data": [
            {
              "key": "Country Provenance",
              "value": "IRELAND"
            },
            {
              "key": "Acknowledgment",
              "value": "The Participant has received and reviewed the Plan and the Award Agreement."
            },
            {
              "key": "Vesting Sections Approved",
              "value": "Vesting of RSUs, Responsibility for Taxes, Electronic Delivery and Participation, Insider Trading Restrictions, Market Abuse Laws, Imposition of Other Requirements, Nature of Grant"
            },
            {
              "key": "Tax Requirements Italy",
              "value": "Reporting of foreign financial assets on annual tax return (UNICO Form, RW Schedule). Foreign asset tax at 0.2%."
            },
            {
              "key": "Foreign Asset Tax Threshold Italy",
              "value": "No tax duties if value is below threshold."
            },
            {
              "key": "Japan Notification",
              "value": "Securities Acquisition Report required for acquisition over ¥100,000,000."
            },
            {
              "key": "Reporting Assets Japan Value",
              "value": "Report if exceeding ¥50,000,000 on December 31st."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": true,
      "elements": [
        {
          "type": "layoff",
          "page": 71,
          "title": "Financial Statement Balance Analysis",
          "data": [
            {
              "key": "Balance, beginning of the year",
              "value": "$10,226k"
            },
            {
              "key": "Cost of Goods Sold",
              "value": "$1,494k"
            },
            {
              "key": "Research and development",
              "value": "$72k"
            },
            {
              "key": "Selling, general and administrative",
              "value": "$5,582k"
            },
            {
              "key": "Payments and other adjustments",
              "value": "-$12,267k"
            },
            {
              "key": "Balance, end of the year",
              "value": "$5,107k"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 42,
          "title": "Cash Flows from Financing Activities",
          "data": [
            {
              "key": "uses",
              "value": "Use of cash from financing activities include:\n1. Purchase of treasury stock: $125.0 million\n2. Cash taxes paid in net equity settlements: $24.6 million due to former CEO departure.\n3. Repayments under Senior Credit Facility and Securitization Facility: $148.6 million offset by $40.8 million borrowings."
            },
            {
              "key": "share_repurchases",
              "value": "On January 12, 2022, entered into a $125 million accelerated share repurchase (2022 ASR), receiving 1.48 million shares, with an additional 0.46 million shares settled on March 24, 2022. Board authorized up to $225 million for share repurchase program, expiring December 2024."
            },
            {
              "key": "dividend_policy",
              "value": "No cash dividends have been paid since formation; future payments depend on Board discretion and financial condition."
            },
            {
              "key": "capital_resources",
              "value": "Sufficient cash and borrowings under Senior Credit Facility to finance operations and capital expenditures for next twelve months."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 43,
          "title": "Off-Balance Sheet Arrangements and Employee Termination Benefits",
          "data": [
            {
              "key": "off_balance_sheet_arrangements",
              "value": "No off-balance sheet financing arrangements during the year-ended December 31, 2022."
            },
            {
              "key": "contractual_obligations",
              "value": "Cash requirements for seasonal working capital, capital expenditures, paying interest, servicing debt, and funding acquisitions."
            },
            {
              "key": "employee_termination_benefits",
              "value": "Employee termination costs due to restructuring activities associated with closure of a manufacturing facility in France and executive reorganization."
            },
            {
              "key": "critical_accounting_policies",
              "value": "Discussion on financial conditions based on GAAP and the significant estimates affecting amounts reported."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 47,
          "title": "Foreign Currency Exchange and Other Rate Risks",
          "data": [
            {
              "key": "Foreign currency risks",
              "value": "Exposure to changes in foreign currency exchange rates affecting financial condition and results."
            },
            {
              "key": "Interest Rate Risk on Cash and Cash Equivalents",
              "value": "Risk of fluctuations on interest income from cash and cash equivalents."
            },
            {
              "key": "USD LIBOR Loan Portfolio Summary",
              "value": "Total portfolio of USD LIBOR loans is approximately $1.475 million."
            },
            {
              "key": "Loan Types",
              "value": "Various terms with amounts ranging from $75,000 to $575,000."
            },
            {
              "key": "Interest Rates",
              "value": "Rates vary from 1.404% to 3.220%."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 52,
          "title": "Corporate Documents and Agreements Summary",
          "data": [
            {
              "key": "Reference",
              "value": "10.3(c) - Amendment to the Second Amended and Restated 2003 Equity Incentive Plan effective January 1, 2013"
            },
            {
              "key": "Reference",
              "value": "10.3(d) - Third Amended and Restated 2003 Equity Incentive Plan effective May 22, 2015"
            },
            {
              "key": "Reference",
              "value": "10.3(e) - Fourth Amended and Restated 2003 Equity Incentive Plan, effective May 23, 2017"
            },
            {
              "key": "Reference",
              "value": "10.3(f) - Amendment to the Integra LifeSciences Holdings Corporation Fourth Amended and Restated 2003 Equity Incentive Plan"
            },
            {
              "key": "Reference",
              "value": "10.3(g) - Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan"
            },
            {
              "key": "Reference",
              "value": "10.4 - Form of Indemnification Agreement"
            },
            {
              "key": "Reference",
              "value": "10.5 - Annual Executive Physical Medical Exam Arrangement"
            },
            {
              "key": "Reference",
              "value": "10.6 - 2018 Performance Incentive Compensation Plan"
            },
            {
              "key": "Reference",
              "value": "10.7 - Integra LifeSciences Holdings Corporation Change in Control Severance Program"
            },
            {
              "key": "Reference",
              "value": "10.8 - Amended and Restated Management Incentive Compensation Plan"
            },
            {
              "key": "Reference",
              "value": "10.9 - Employment Agreement with Jan De Witte"
            },
            {
              "key": "Reference",
              "value": "10.10 - Davis Promotion Summary"
            },
            {
              "key": "Reference",
              "value": "10.11(a) - Coleman Promotion Summary"
            },
            {
              "key": "Reference",
              "value": "10.11(b) - Separation Agreement and General Release with Glenn Coleman"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 72,
          "title": "Pension Benefits and Deferred Compensation Plan",
          "data": [
            {
              "key": "Pension Benefit Plans",
              "value": "Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany and Switzerland."
            },
            {
              "key": "Key Assumptions",
              "value": "Discount rate based on average rates on bonds that match expected cash outflows; expected return based on historical returns."
            },
            {
              "key": "Deferred Compensation Plan",
              "value": "Allows certain employees to defer up to 75% of base salary and 100% of bonus, invested in funds."
            },
            {
              "key": "Concentration of Credit Risk",
              "value": "Financial instruments primarily consist of cash, marketable debt securities, and trade receivables."
            },
            {
              "key": "Recent Accounting Pronouncements",
              "value": "Company adopted ASU 2019-12 to simplify accounting for income taxes, effective January 1, 2021."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 92,
          "title": "Option Valuation Metrics and Assumptions",
          "data": [
            {
              "key": "Dividend yield",
              "value": "0%"
            },
            {
              "key": "Expected volatility",
              "value": "30%"
            },
            {
              "key": "Risk free interest rate",
              "value": "2.01%"
            },
            {
              "key": "Expected life of option from grant date",
              "value": "7 years"
            },
            {
              "key": "Weighted average grant date fair value of options granted",
              "value": "$23.15"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 92,
          "title": "Stock Options Activity Summary 2022",
          "data": [
            {
              "key": "Outstanding at January 1, 2022",
              "value": "1,225,000"
            },
            {
              "key": "Granted",
              "value": "146,000"
            },
            {
              "key": "Exercised",
              "value": "-155,000"
            },
            {
              "key": "Forfeited or Expired",
              "value": "-14,000"
            },
            {
              "key": "Outstanding at December 31, 2022",
              "value": "1,202,000"
            },
            {
              "key": "Exercisable at December 31, 2022",
              "value": "871,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 93,
          "title": "Share-Based Compensation Awards Movement",
          "data": [
            {
              "key": "Expense related to awards 2022",
              "value": "$24.3 million"
            },
            {
              "key": "Expense related to awards 2021",
              "value": "$31.2 million"
            },
            {
              "key": "Expense related to awards 2020",
              "value": "$16.4 million"
            },
            {
              "key": "Total fair market value of shares vested 2022",
              "value": "$65.0 million"
            },
            {
              "key": "Total fair market value of shares vested 2021",
              "value": "$15.7 million"
            },
            {
              "key": "Total fair market value of shares vested 2020",
              "value": "$17.3 million"
            },
            {
              "key": "Unrecognized compensation costs of unvested awards 2022",
              "value": "$29.7 million"
            },
            {
              "key": "Recognition over period for unvested awards",
              "value": "Approximately 2 years"
            },
            {
              "key": "Shares available under 2003 Plan",
              "value": "Approximately 3.1 million"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 96,
          "title": "Summary of Expected Future Benefit Payments and Compensation Contributions",
          "data": [
            {
              "key": "2023 expected payment (in thousands)",
              "value": "2211"
            },
            {
              "key": "2024 expected payment (in thousands)",
              "value": "2045"
            },
            {
              "key": "2025 expected payment (in thousands)",
              "value": "2050"
            },
            {
              "key": "2026 expected payment (in thousands)",
              "value": "1929"
            },
            {
              "key": "2027 expected payment (in thousands)",
              "value": "1868"
            },
            {
              "key": "Next five years total expected payments (in thousands)",
              "value": "11068"
            },
            {
              "key": "Total contributions made by the Company for defined contribution plans (2022)",
              "value": "9800000"
            },
            {
              "key": "Total contributions made by the Company for defined contribution plans (2021)",
              "value": "8800000"
            },
            {
              "key": "Total contributions made by the Company for defined contribution plans (2020)",
              "value": "6700000"
            },
            {
              "key": "Deferred compensation plan fair value (2022)",
              "value": "4700000"
            },
            {
              "key": "Deferred compensation plan fair value (2021)",
              "value": "3800000"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 108,
          "title": "Disclosure of Proposing Person Interests",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Description of Business Proposal",
              "value": "A reasonably brief description of the business desired to be brought before the annual meeting, the reasons for conducting such business at the annual meeting and any material interest in such business of each Proposing Person."
            },
            {
              "key": "Disclosable Interests",
              "value": "Any rights to dividends, interests in contracts with the Corporation, pending litigation involving the Corporation, and material transactions between Proposing Persons and the Corporation."
            },
            {
              "key": "Performance Related Fees",
              "value": "Any performance related fees (other than an asset based fee) based on price changes of shares."
            },
            {
              "key": "Responsible Person's Qualifications",
              "value": "Qualifications and background of any Responsible Person associated with Proposing Persons."
            },
            {
              "key": "Competitor Interests",
              "value": "Any equity interests or Synthetic Equity Interests in principal competitors of the Corporation."
            },
            {
              "key": "Litigation",
              "value": "Any pending or threatened litigation involving the Proposing Person."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 130,
          "title": "RESTRICTED STOCK AGREEMENT",
          "data": [
            {
              "key": "Award Agreement Date",
              "value": "[ ]"
            },
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Holdings Corporation"
            },
            {
              "key": "Award Date",
              "value": "[ ]"
            },
            {
              "key": "Restricted Stock Shares",
              "value": "[ ]"
            },
            {
              "key": "Plan Name",
              "value": "Integra LifeSciences Holdings Corporation 2003 Equity Incentive Plan"
            },
            {
              "key": "Vesting Date",
              "value": "Each twelve-month anniversary of the Award Date"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 131,
          "title": "Issuance of Restricted Stock",
          "data": [
            {
              "key": "Issuance date",
              "value": "On the date hereof"
            },
            {
              "key": "Conditions for issuing",
              "value": "Restricted Stock subject to the Restrictions and other conditions set forth in this Award Agreement"
            },
            {
              "key": "Voting rights",
              "value": "Participant shall have all the rights of a stockholder with respect to his Restricted Stock"
            },
            {
              "key": "Dividend rights",
              "value": "Right to receive all dividends or other distributions paid or made with respect to only those outstanding vested shares of Common Stock"
            },
            {
              "key": "Forfeiture conditions",
              "value": "Upon the Participant’s Termination of Service other than by death or Disability"
            },
            {
              "key": "Change in Control provision",
              "value": "All Restrictions shall lapse and all Restricted Stock shall become Vested Shares upon a Change in Control with Qualifying Termination"
            },
            {
              "key": "Vesting condition",
              "value": "Participant must continue to serve as an employee or Associate from the Award Date to the Vesting Date"
            },
            {
              "key": "Vesting date",
              "value": "Shares shall vest on the Vesting Date as provided in Section 3.3"
            },
            {
              "key": "New certificate issuance",
              "value": "Company shall issue new certificates evidencing Vested Shares upon vesting."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 132,
          "title": "Restricted Stock Agreement",
          "data": [
            {
              "key": "Company",
              "value": "Integra Lifesciences Holdings Corporation"
            },
            {
              "key": "Vesting Date",
              "value": "N/A"
            },
            {
              "key": "Tax Withholding",
              "value": "Company to notify Participant of tax to be withheld on Vesting Date"
            },
            {
              "key": "Clawback Policy",
              "value": "Subject to clawback, repayment or recapture policy"
            },
            {
              "key": "Address of Corporation",
              "value": "1100 Campus Drive, Princeton, New Jersey 08540"
            },
            {
              "key": "Legend for Certificates",
              "value": "Securities subject to vesting requirements and potential forfeiture before ownership vests"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 133,
          "title": "Award Agreement Provisions",
          "data": [
            {
              "key": "Document Type",
              "value": "Award Agreement"
            },
            {
              "key": "Securities Compliance",
              "value": "Intended to conform with Securities Act and Exchange Act regulations"
            },
            {
              "key": "Governing Law",
              "value": "Laws of the State of Delaware"
            },
            {
              "key": "Amendment Clause",
              "value": "This Award Agreement may be amended only by a writing executed by the parties."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 134,
          "title": "Exhibit 10.3(h)",
          "data": [
            {
              "key": "Document Type",
              "value": "Exhibit"
            },
            {
              "key": "Topic",
              "value": "Executive Compensation"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 135,
          "title": "Restricted Stock Agreement",
          "data": [
            {
              "key": "Award Agreement",
              "value": "Restricted Stock Agreement between Integra LifeSciences Holdings Corporation and Participant."
            },
            {
              "key": "Award Date",
              "value": "[ ]"
            },
            {
              "key": "Company",
              "value": "Integra LifeSciences Holdings Corporation"
            },
            {
              "key": "Plan",
              "value": "Fifth Amended and Restated 2003 Equity Incentive Plan"
            },
            {
              "key": "Restricted Stock",
              "value": "[ ] shares of Common Stock"
            },
            {
              "key": "Restrictions",
              "value": "Forfeiture and transferability restrictions upon Restricted Stock."
            },
            {
              "key": "Termination of Service",
              "value": "Time when Participant ceases to provide services to the Company."
            },
            {
              "key": "Vested Shares",
              "value": "Shares of Restricted Stock no longer subject to Restrictions."
            },
            {
              "key": "Vesting Date",
              "value": "Each of the first, second and third anniversaries of the Award Date."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 136,
          "title": "Issuance of Restricted Stock and Conditions",
          "data": [
            {
              "key": "Issuance Date",
              "value": "Date hereof"
            },
            {
              "key": "Vesting Conditions",
              "value": "Until vested pursuant to Section 3.2"
            },
            {
              "key": "Forfeiture Conditions",
              "value": "Upon Participant’s Termination of Service unless by death or Disability"
            },
            {
              "key": "Voting Rights",
              "value": "Participant shall have all rights of a stockholder except for certain conditions"
            },
            {
              "key": "Dividend Rights",
              "value": "Dividends only on outstanding vested shares"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 137,
          "title": "Restricted Stock Agreement Provisions",
          "data": [
            {
              "key": "Section 4.3",
              "value": "Tax Withholding provisions."
            },
            {
              "key": "Section 4.1",
              "value": "No Additional Rights concerning employment."
            },
            {
              "key": "Section 4.2",
              "value": "Legend for Restricted Stock certificates."
            },
            {
              "key": "Section 3.4",
              "value": "Clawback provisions and applicable laws."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 138,
          "title": "Award Agreement",
          "data": [
            {
              "key": "Fair Market Value",
              "value": "determined as of each Vesting Date, not in excess of the minimum of tax required to be withheld by law."
            },
            {
              "key": "Notices",
              "value": "Any notice to be given under the terms of this Award Agreement to the Company shall be addressed to the Company in care of its Secretary."
            },
            {
              "key": "Titles",
              "value": "Provided for convenience only and are not to serve as a basis for interpretation."
            },
            {
              "key": "Conformity to Securities Laws",
              "value": "Intended to conform to the provisions of the Securities Act and the Exchange Act."
            },
            {
              "key": "Amendment",
              "value": "May be amended only by writing executed by the parties."
            },
            {
              "key": "Governing Law",
              "value": "Laws of the State of Delaware shall govern the interpretation and validity."
            },
            {
              "key": "Electronic Delivery and Acceptance",
              "value": "Participant consents to receive documents by electronic delivery."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 139,
          "title": "Award Agreement",
          "data": [
            {
              "key": "Conditions",
              "value": "conditions set forth in the Plan"
            },
            {
              "key": "Execution",
              "value": "this Award Agreement has been executed and delivered by the parties hereto."
            },
            {
              "key": "Company Name",
              "value": "INTEGRA LIFESCIENCES"
            },
            {
              "key": "Participant Holdings Corporation",
              "value": "THE PARTICIPANT HOLDINGS CORPORATION"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 140,
          "title": "Performance Stock Agreement",
          "data": [
            {
              "key": "Award Date",
              "value": "[ ]"
            },
            {
              "key": "Company",
              "value": "Integra LifeSciences Holdings Corporation"
            },
            {
              "key": "Annual Organic Revenue",
              "value": "Company’s gross revenue excluding currency exchange effects, acquired revenues, product discontinuances, and divestitures"
            },
            {
              "key": "Catch-Up Performance Goal",
              "value": "Specific goal determined by the Committee, specified in Exhibit A"
            },
            {
              "key": "Catch-Up Shares",
              "value": "Defined in Exhibit A"
            },
            {
              "key": "Change in Control",
              "value": "As defined in the Plan"
            },
            {
              "key": "Chief Human Resources Officer",
              "value": "Chief Human Resources Officer of the Company"
            },
            {
              "key": "Good Reason",
              "value": "As defined in the Plan"
            },
            {
              "key": "Performance Goals",
              "value": "Specific goals determined by the Committee, specified in Exhibit A"
            },
            {
              "key": "Performance Period",
              "value": "Periods that the Performance Goals must be met, specified in Exhibit A"
            },
            {
              "key": "Performance-Vest",
              "value": "When the applicable Performance Goal has been achieved"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 142,
          "title": "Performance Stock Vesting and Termination Conditions",
          "data": [
            {
              "key": "Voting Rights",
              "value": "The Participant shall not have any voting rights in respect of the shares of Performance Stock until such Shares shall have been issued by the Company."
            },
            {
              "key": "Vesting Schedule",
              "value": "(i) 33% of Target Performance Shares Vest on the first anniversary of the Award Date; (ii) 33% of Target Performance Shares Vest on the second anniversary of the Award Date; (iii) 34% of Target Performance Shares Vest on the third anniversary of the Award Date."
            },
            {
              "key": "Termination of Service Effects",
              "value": "In case of Disability or death, shares not vested will remain outstanding and eligible to vest; otherwise, they will be forfeited."
            },
            {
              "key": "Catch-Up Performance Goal",
              "value": "If achieved, any Catch-Up Shares shall Vest on the third anniversary of the Award Date."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 143,
          "title": "Performance Stock Vesting Terms",
          "data": [
            {
              "key": "Termination of Service",
              "value": "Participant shall have no further right to Performance Stock if terminated."
            },
            {
              "key": "Change in Control",
              "value": "Shares not vested shall be forfeited as of such Change in Control."
            },
            {
              "key": "Third Anniversary Vesting",
              "value": "Shares unvested by the third anniversary shall be automatically canceled."
            },
            {
              "key": "Issuance of Shares",
              "value": "Shares issued within five business days post vesting."
            },
            {
              "key": "Clawback Policy",
              "value": "Shares subject to clawback provisions as per policies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 144,
          "title": "Performance Stock Vesting Conditions",
          "data": [
            {
              "key": "Performance Goal Achievement",
              "value": "The Company's actual achievement of the Performance Goal for such year through the Change in Control."
            },
            {
              "key": "Continuous Service Requirement",
              "value": "Subject to the Participant’s continuous service."
            },
            {
              "key": "Vesting Conditions after Change in Control",
              "value": "Performance-Vested shares remain outstanding and eligible to Vest on the anniversary of the Award Date following the Change in Control."
            },
            {
              "key": "Shares Vesting with Performance Stock",
              "value": "A number of shares of Performance Stock shall Performance-Vest equal to the number of shares that could vest with respect to each fiscal year."
            },
            {
              "key": "Qualifying Termination Vesting",
              "value": "Performance-Vested shares of Performance Stock shall Vest in full upon Qualifying Termination within twelve months of Change in Control."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 145,
          "title": "Award Agreement Sections on Tax and Notice Provisions",
          "data": [
            {
              "key": "Fair Market Value",
              "value": "Aggregate amount of liabilities for tax purposes based on minimum statutory withholding rates."
            },
            {
              "key": "Shares Withheld",
              "value": "Rounded up to the nearest whole share."
            },
            {
              "key": "Notices",
              "value": "Addressed to Chief Human Resources Officer or Participant’s address."
            },
            {
              "key": "Governing Law",
              "value": "State of Delaware."
            },
            {
              "key": "Securities Laws Compliance",
              "value": "Intended to conform to Securities Act and Exchange Act including Rule 16b-3."
            },
            {
              "key": "Amendment",
              "value": "Can only be amended in writing by parties."
            },
            {
              "key": "Section 409A",
              "value": "Payment under this agreement is governed by Section 409A of the Code."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 146,
          "title": "Executive Compensation and Payment Terms",
          "data": [
            {
              "key": "Payment Delay Clause",
              "value": "No amounts payable before the expiration of the 6-month period following the Participant’s separation from service."
            },
            {
              "key": "Payment Condition",
              "value": "Payments may be delayed if deemed a prohibited distribution under Section 409A."
            },
            {
              "key": "Cumulative Payment",
              "value": "Lump-sum payment equal to cumulative amount after the 6-month period."
            },
            {
              "key": "Electronic Delivery Consent",
              "value": "Participant consents to receive documents and awards electronically."
            },
            {
              "key": "Acceptance of Terms",
              "value": "Clicking 'ACCEPT' acts as electronic signature and forms a contract."
            },
            {
              "key": "Conflict Resolution",
              "value": "Terms in the Plan shall prevail over this Award Agreement if there are any conflicts."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 148,
          "title": "Performance Goals and Performance Period",
          "data": [
            {
              "key": "Performance Period",
              "value": "three-year period beginning [ ] and ending [ ]"
            },
            {
              "key": "Catch-Up Performance Goal",
              "value": "achieves an average 3-year Annual Organic Revenue growth rate of at least [ ]%."
            },
            {
              "key": "Performance Goal",
              "value": "achieves a Threshold Level or higher level of growth in Annual Organic Revenue over the immediately preceding fiscal year."
            },
            {
              "key": "Summary",
              "value": "This table appears to be a performance vesting schedule that shows the relationship between organic revenue growth and vesting percentages."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 149,
          "title": "Performance Stock Vesting",
          "data": [
            {
              "key": "Fiscal Year",
              "value": "(y)"
            },
            {
              "key": "Vesting Percentage",
              "value": "Applicable Performance Vesting Percentage"
            },
            {
              "key": "Catch-Up Shares",
              "value": "Vested shares as per agreement"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 150,
          "title": "Non-Qualified Stock Option Agreement",
          "data": [
            {
              "key": "Company",
              "value": "Integra LifeSciences Holdings Corporation"
            },
            {
              "key": "Grant Type",
              "value": "Non-Qualified Stock Option"
            },
            {
              "key": "Plan Name",
              "value": "2003 Equity Incentive Plan"
            },
            {
              "key": "Vesting Schedule",
              "value": "25% each year on the first, second, third, and fourth anniversaries of the grant date"
            },
            {
              "key": "Exercise Price Determination",
              "value": "Not less than 100% of fair market value or par value"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 151,
          "title": "Option Agreement Terms",
          "data": [
            {
              "key": "Option Vesting Termination",
              "value": "No portion of the Option becomes vested upon termination of employment."
            },
            {
              "key": "Method of Exercising Option",
              "value": "Written notice to the Company at its principal office."
            },
            {
              "key": "Payment Methods for Option Price",
              "value": "Cash, cash equivalent, Common Stock, combination thereof."
            },
            {
              "key": "Investment Intent",
              "value": "Shares acquired must be for investment purposes."
            },
            {
              "key": "Non-Transferability",
              "value": "Option is not assignable or transferable."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 152,
          "title": "Termination of Employment",
          "data": [
            {
              "key": "Termination Conditions",
              "value": "Employee's employment is terminated for any reason other than death, disability, or a Qualifying Termination upon a Change in Control."
            },
            {
              "key": "Option Exercise Period",
              "value": "Option may be exercised before the Expiration Date or six months after termination."
            },
            {
              "key": "Death Provision",
              "value": "If Employee dies, Option becomes fully vested and can be exercised by the estate or beneficiary up to one year after death."
            },
            {
              "key": "Disability Provision",
              "value": "If terminated due to disability, Option becomes fully vested and can be exercised by Employee or legal representative up to one year after termination."
            },
            {
              "key": "Change in Control Provision",
              "value": "If Change in Control occurs and Employee has a Qualifying Termination within 12 months, Option becomes fully vested."
            },
            {
              "key": "Clawback Policy",
              "value": "Option is subject to clawback, repayment, or recapture policies as per law."
            },
            {
              "key": "Tax Withholding",
              "value": "Obligation to deliver shares is subject to federal, state, and local tax withholding requirements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 153,
          "title": "Non-Qualified Stock Option Agreement",
          "data": [
            {
              "key": "Tax Withholding Requirement",
              "value": "An election to use shares of Common Stock to satisfy tax withholding requirements must be made in compliance with and subject to the Withholding Rules."
            },
            {
              "key": "Committee Restrictions",
              "value": "The Committee may not withhold shares in excess of the number necessary to satisfy the minimum tax withholding requirements."
            },
            {
              "key": "Governing Law",
              "value": "This Non-Qualified Stock Option Agreement shall be governed by applicable federal law and otherwise by the laws of the State of Delaware."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 153,
          "title": "Signature Block",
          "data": [
            {
              "key": "Electronic Signature Process",
              "value": "Electronic signature to be provided and recorded via online grant acceptance process on www.etrade.com."
            },
            {
              "key": "Company Name",
              "value": "INTEGRA LIFESCIENCES HOLDINGS CORPORATION"
            },
            {
              "key": "Signature Placeholder",
              "value": "By. Name: Title:"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 154,
          "title": "Restricted Stock Unit Award Agreement",
          "data": [
            {
              "key": "Company",
              "value": "Integra LifeSciences Holdings Corporation"
            },
            {
              "key": "Type of Award",
              "value": "Restricted Stock Units (RSUs)"
            },
            {
              "key": "Award Date",
              "value": "[ ]"
            },
            {
              "key": "Purpose",
              "value": "Incentive for increased efforts during employment"
            },
            {
              "key": "Applicable Plan",
              "value": "Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 155,
          "title": "Grant of Restricted Stock Units and Issuance of Shares",
          "data": [
            {
              "key": "Meaning of Plan",
              "value": "Set forth in the recitals."
            },
            {
              "key": "RSUs Definition",
              "value": "A conditional right to receive Shares upon vesting and settlement."
            },
            {
              "key": "Secretary Definition",
              "value": "The Secretary of the Company."
            },
            {
              "key": "Service Recipient Definition",
              "value": "The Company, Related Corporation or Affiliate with which the Participant has an employment or service relationship."
            },
            {
              "key": "Termination Date Definition",
              "value": "The date the Participant is no longer actively providing services to the Company."
            },
            {
              "key": "Grant of RSUs",
              "value": "The Company hereby grants RSUs to the Participant as of the Award Date."
            },
            {
              "key": "Vesting Schedule",
              "value": "33% vest on first and second anniversary, 34% on third anniversary."
            },
            {
              "key": "Termination of Service Condition",
              "value": "Termination other than by death or Disability or a Qualifying Termination post-Change in Control."
            },
            {
              "key": "Impact of Death or Disability on RSUs",
              "value": "All RSUs held by the Participant prior to death or Disability will vest."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 156,
          "title": "Exhibit 10.3 - Vesting and Acceleration of RSUs",
          "data": [
            {
              "key": "Vesting Conditions",
              "value": "RSUs shall become fully vested upon Participant's death or Disability."
            },
            {
              "key": "Change in Control",
              "value": "If a Change in Control occurs, RSUs shall become fully vested upon Qualifying Termination within 12 months following the Change in Control."
            },
            {
              "key": "Acceleration of Vesting",
              "value": "Committee may permit vesting of RSUs prior to Vesting Date."
            },
            {
              "key": "U.S. Taxpayer Payments",
              "value": "Payments for Shares upon vesting comply with Section 409A."
            },
            {
              "key": "Settlement Timing",
              "value": "Shares issued as soon as practicable following each Vesting Date."
            },
            {
              "key": "Fractional Shares",
              "value": "No fractional Shares will be issued."
            },
            {
              "key": "Section 409A Compliance",
              "value": "Intent to comply with Section 409A to avoid additional taxes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 157,
          "title": "Adjustments to Restricted Stock Units and Grant Conditions",
          "data": [
            {
              "key": "Adjustments",
              "value": "Any subdivision, consolidation, stock dividend, capital reorganization, etc. will adjust the Participant's account and RSUs to preserve their interests."
            },
            {
              "key": "Forfeiture/Clawback",
              "value": "RSUs subject to clawback policies as per applicable laws, including Dodd-Frank."
            },
            {
              "key": "Status of Plan",
              "value": "If there's a conflict between the Plan and Award Agreement, the Plan governs."
            },
            {
              "key": "Committee’s Authority",
              "value": "The Committee interprets the Plan, adopts rules, and its actions are final and binding."
            },
            {
              "key": "Nature of Grant",
              "value": "The grant of RSUs does not create future rights to grants or benefits."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 158,
          "title": "RSUs and Shares Compensation Structure",
          "data": [
            {
              "key": "RSUs Compensation",
              "value": "The RSUs and Shares are not granted as consideration for any service the Participant may provide as a director of a Related Corporation or an Affiliate."
            },
            {
              "key": "Ineligibility for Normal Compensation",
              "value": "The RSUs and Shares are not part of normal or expected compensation with respect to severance, bonuses, pensions, or similar payments."
            },
            {
              "key": "Unpredictable Future Value",
              "value": "The future value of the Shares underlying the RSUs is unknown and cannot be predicted."
            },
            {
              "key": "Forfeiture of RSUs",
              "value": "No claim for damages arises from forfeiture of RSUs resulting from employment termination."
            },
            {
              "key": "Liability for Exchange Rate Fluctuation",
              "value": "The Company is not liable for exchange rate fluctuations affecting the value of RSUs."
            },
            {
              "key": "No Financial Advice Provided",
              "value": "The Company does not provide tax, legal, or financial advice regarding the Plan."
            },
            {
              "key": "Responsibility for Taxes",
              "value": "The Participant is responsible for all tax-related items linked to their participation in the Plan."
            },
            {
              "key": "Multi-jurisdiction Tax Liability",
              "value": "The Participant acknowledges tax liability in more than one jurisdiction may affect withholding requirements."
            },
            {
              "key": "Tax Withholding Arrangements",
              "value": "The Participant agrees to make satisfactory arrangements for tax withholding events."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 159,
          "title": "Tax-Related Items and Withholding Obligations",
          "data": [
            {
              "key": "Tax Withholding Methods",
              "value": "The Company or Service Recipient may satisfy withholding obligations through various methods including: withholding from wages, requiring cash payment, withholding from proceeds of stock sales, or withholding in Shares."
            },
            {
              "key": "Over-Withholding and Refunds",
              "value": "If over-withholding occurs, the Participant may receive a refund in cash, or seek a refund from tax authorities."
            },
            {
              "key": "Under-Withholding",
              "value": "The Participant may need to pay additional Tax-Related Items directly to tax authorities or the Company."
            },
            {
              "key": "Agreement to Tax Obligations",
              "value": "The Participant agrees to pay any required Tax-Related Items that cannot be satisfied by previous means."
            },
            {
              "key": "Tax Consequences Review",
              "value": "The Participant has consulted their tax advisors about applicable tax consequences of their investment."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 160,
          "title": "RSUs Award Agreement Terms and Conditions",
          "data": [
            {
              "key": "Unfunded and Unsecured Plan",
              "value": "The plan is unfunded and the Company's obligations under the plan and this Award Agreement are unsecured."
            },
            {
              "key": "No Stockholder Rights",
              "value": "RSUs shall not be considered Shares or other securities of the Company, nor do they entitle the Participant to vote or receive dividends."
            },
            {
              "key": "No Guarantee of Continued Employment",
              "value": "Vesting of RSUs is only earned by continuing as an employee or service provider, not through being granted the award."
            },
            {
              "key": "Notices",
              "value": "Notices must be addressed to the Company Secretary and to the Participant at their provided addresses."
            },
            {
              "key": "Compliance with Laws",
              "value": "The Company is not required to issue Shares until completion of all legal requirements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 161,
          "title": "RSUs Award Agreement",
          "data": [
            {
              "key": "Approval requirements",
              "value": "Company shall, in its absolute discretion, deem necessary or advisable for obtaining any approval or other clearance from any U.S. or non-U.S. governmental agency."
            },
            {
              "key": "Unilateral authority",
              "value": "Company shall have unilateral authority to amend this Award Agreement without the Participant’s consent."
            },
            {
              "key": "Modifications",
              "value": "Modifications can be made only in an express written contract executed by a duly authorized officer of the Company."
            },
            {
              "key": "Plan amendment",
              "value": "The Plan is discretionary in nature and may be amended, suspended, or terminated by the Company at any time."
            },
            {
              "key": "Governing Law",
              "value": "Laws of the State of Delaware shall govern the interpretation and enforcement of this Award Agreement."
            },
            {
              "key": "Jurisdiction",
              "value": "Parties consent to jurisdiction of the State of New Jersey for any disputes."
            },
            {
              "key": "Assignment",
              "value": "Rights and obligations may be assigned by the Company to a successor in the business."
            },
            {
              "key": "Consent to data activities",
              "value": "Participant expressly consents to the Company’s data collection, processing, and transfer practices."
            },
            {
              "key": "Personal data collected",
              "value": "Participant's name, home address, email address, telephone number, date of birth, and social insurance number."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 162,
          "title": "Executive Compensation - RSU Plan Details",
          "data": [
            {
              "key": "number",
              "value": "RSU Plan Number 10.3(l)"
            },
            {
              "key": "salary",
              "value": "N/A"
            },
            {
              "key": "citizenship",
              "value": "N/A"
            },
            {
              "key": "job_title",
              "value": "Participant"
            },
            {
              "key": "shares_or_directorships",
              "value": "Details not specified"
            },
            {
              "key": "equity_compensation_awards",
              "value": "RSUs granted, canceled, exercised, vested, outstanding"
            },
            {
              "key": "personal_data_usage",
              "value": "Participant’s consent required for data collection"
            },
            {
              "key": "stock_plan_administrator",
              "value": "E*TRADE Securities LLC, American Stock Transfer & Trust Company, LLC"
            },
            {
              "key": "international_data_transfer",
              "value": "Participant’s consent required for data transfer to the US"
            },
            {
              "key": "voluntariness",
              "value": "Participation is voluntary; consent can be withdrawn"
            },
            {
              "key": "data_subjects_rights",
              "value": "Access, rectification, deletion, processing restrictions, complaints"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 163,
          "title": "Grant of Award and Award Agreement",
          "data": [
            {
              "key": "Award Cancellation",
              "value": "If the Participant properly declines the Award, the Award will be cancelled and the Participant will not be entitled to any benefits from the Award or any compensation or benefits in lieu of the cancelled Award."
            },
            {
              "key": "Waivers",
              "value": "No waiver by either party of any breach of, or of compliance with, any condition or provision of this Award Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time."
            },
            {
              "key": "Entire Agreement",
              "value": "The Notice of Grant of Award, this Award Agreement, and the Plan constitute the entire contract between the parties hereto with regard to the subject matter hereof."
            },
            {
              "key": "Severability",
              "value": "The provisions of this Award Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, the remaining provisions shall nevertheless be binding and enforceable."
            },
            {
              "key": "Language Control",
              "value": "If the Participant has received this Award Agreement translated into a language other than English, the English version will control."
            },
            {
              "key": "Foreign Reporting and Tax Requirements",
              "value": "The Participant must comply with foreign asset and/or account reporting requirements, exchange controls, and tax payment obligations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 164,
          "title": "Market Abuse Laws and Insider Trading Policy",
          "data": [
            {
              "key": "Description",
              "value": "Details about restrictions on Participants related to market-abuse laws and insider trading regulations affecting the acceptance and disposition of Shares."
            },
            {
              "key": "Responsibilities",
              "value": "Participants must comply with local laws and the Company's insider trading policy."
            },
            {
              "key": "Legal Advisory",
              "value": "Participants should consult their personal legal advisors regarding compliance."
            },
            {
              "key": "Section",
              "value": "3.24 Imposition of Other Requirements"
            },
            {
              "key": "Additional Requirements",
              "value": "Company may impose other requirements necessary for legal or administrative reasons."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 166,
          "title": "Exhibit A - Integra Lifesciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Restricted Stock Unit Award Agreement",
          "data": [
            {
              "key": "Document Description",
              "value": "This Exhibit A includes special terms and conditions applicable to the Participant if they reside and/or work outside the U.S. and includes information regarding tax, securities law, exchange controls pertaining to the Plan."
            },
            {
              "key": "Important Considerations",
              "value": "Participants should not rely solely on the information provided as laws change frequently and may not apply to individual situations."
            },
            {
              "key": "Professional Advice",
              "value": "The Company advises Participants to seek professional advice on how relevant laws apply to their specific situation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 167,
          "title": "EUROPEAN UNION/EUROPEAN ECONOMIC AREA Terms and Conditions",
          "data": [
            {
              "key": "Company Name",
              "value": "N/A"
            },
            {
              "key": "Company Address",
              "value": "1100 Campus Road, Princeton, New Jersey 08540, United States of America"
            },
            {
              "key": "Data Collected",
              "value": "Participant’s name, home address, email address, telephone number, date of birth, social insurance number, salary, citizenship, job title, Shares or directorships held, details of RSUs or other equity compensation awards."
            },
            {
              "key": "Purpose of Data Collection",
              "value": "Allocating Shares, administering and managing the Plan."
            },
            {
              "key": "Legal Basis for Data Collection",
              "value": "Company legitimate interest of managing the Plan and satisfying contractual obligations."
            },
            {
              "key": "Refusal Consequence",
              "value": "May affect the Participant’s ability to participate in the Plan."
            },
            {
              "key": "Service Providers",
              "value": "E*TRADE Securities LLC, American Stock Transfer & Trust Company, LLC."
            },
            {
              "key": "International Data Transfer Notes",
              "value": "Participant’s country of residence has different data privacy laws than the United States."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 169,
          "title": "RSUs and Tax Information in Belgium and Canada",
          "data": [
            {
              "key": "Country",
              "value": "Belgium"
            },
            {
              "key": "Report Requirements",
              "value": "The Participant must report securities or bank accounts held outside Belgium on their annual tax return."
            },
            {
              "key": "Stock Exchange Tax",
              "value": "A stock exchange tax applies to transactions executed by Belgian residents through non-Belgian financial intermediaries."
            },
            {
              "key": "Annual Securities Account Tax",
              "value": "A 0.15% annual tax applies if the value of securities exceeds €1 million."
            },
            {
              "key": "Country",
              "value": "Canada"
            },
            {
              "key": "RSUs Terms",
              "value": "RSUs and dividend equivalents are payable only in shares."
            },
            {
              "key": "Termination Date Provision",
              "value": "Termination of employment is defined as the earliest of specified conditions."
            }
          ],
          "currency": "EUR"
        },
        {
          "type": "executive_compensation",
          "page": 170,
          "title": "RSUs Participant Rights andConditions",
          "data": [
            {
              "key": "Termination of Vesting",
              "value": "The Participant's right to vest terminates before a specified date."
            },
            {
              "key": "Vesting Compensation",
              "value": "The Participant is not entitled to compensation for lost vesting."
            },
            {
              "key": "Discretion of Committee",
              "value": "The Committee has discretion to determine service provision for vesting."
            },
            {
              "key": "Employment Standards Legislation",
              "value": "Entitlement to vesting during statutory notice is subject to legislation."
            },
            {
              "key": "Quebec Language Consent",
              "value": "The Award Agreement and related documents should be in English."
            },
            {
              "key": "Data Privacy",
              "value": "Participant authorizes collection and sharing of information by the Company."
            },
            {
              "key": "Securities Law Information",
              "value": "Shares can be sold through designated brokers outside Canada."
            },
            {
              "key": "Foreign Asset Reporting",
              "value": "Canadian residents must report foreign specified property exceeding C$100,000."
            },
            {
              "key": "Adjusted Cost Base (ACB)",
              "value": "ACB is based on fair market value at acquisition, may need averaging."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 174,
          "title": "Terms and Conditions Acceptance of the Award Agreement",
          "data": [
            {
              "key": "RSUs Acceptance",
              "value": "Participant acknowledges receipt of the Plan and the Award Agreement."
            },
            {
              "key": "Participant's Acknowledgment",
              "value": "Confirms acceptance of all provisions of the Plan and Award Agreement."
            },
            {
              "key": "Rights Disclosure",
              "value": "Participation in the Plan does not constitute an acquired right."
            },
            {
              "key": "Discretionary Participation",
              "value": "Company offers participation on a wholly discretionary basis."
            },
            {
              "key": "Voluntary Participation",
              "value": "Participation is voluntary."
            },
            {
              "key": "Labor Law Policy",
              "value": "Integra LifeSciences Holdings Corporation is solely responsible for the administration of the Plan."
            },
            {
              "key": "No Employment Relationship",
              "value": "Participation does not create an employment relationship."
            },
            {
              "key": "Company's Amendments Right",
              "value": "Company reserves the right to amend/discontinue participation at any time."
            },
            {
              "key": "Release of Claims",
              "value": "Participant releases claims against the Company."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 175,
          "title": "Plan y participación del Participante en el Plan",
          "data": [
            {
              "key": "Participante",
              "value": "El Participante reconoce expresamente que Integra LifeSciences Holdings Corporation es responsable de la administración del Plan."
            },
            {
              "key": "Participación",
              "value": "La participación del Participante en el Plan es voluntaria."
            },
            {
              "key": "Responsabilidad",
              "value": "La Compañía se reserva el derecho de modificar y/o discontinuar la participación del Participante."
            },
            {
              "key": "Exclusión de Responsabilidad",
              "value": "El Participante exime a la Compañía de cualquier reclamo relacionado con el Plan."
            },
            {
              "key": "Regulación",
              "value": "Los RSUs y Shares no han sido registrados con la Comisión Nacional Bancaria y de Valores de México."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 176,
          "title": "Securities Law Information and Responsibilities for Taxes",
          "data": [
            {
              "key": "Securities Law Information",
              "value": "This Award Agreement does not constitute a prospectus according to Swiss laws and may not be distributed publicly in Switzerland."
            },
            {
              "key": "Tax Responsibility",
              "value": "Participant is liable for all Tax-Related Items and agrees to indemnify the Company against any required payments to HMRC."
            },
            {
              "key": "Notification Requirement",
              "value": "Directors must notify the Singapore Affiliate of interests in the Company within two business days."
            },
            {
              "key": "Stock Market Information",
              "value": "Common Stock traded on NASDAQ under ticker symbol 'IART'."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 177,
          "title": "Executive Compensation Agreement",
          "data": [
            {
              "key": "Regime",
              "value": "Additional Benefit"
            },
            {
              "key": "Company Recovery",
              "value": "Amount of NICs due"
            },
            {
              "key": "Agreement Reference",
              "value": "Section 3.4 of the Award Agreement"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 182,
          "title": "Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002",
          "data": [
            {
              "key": "Certified By",
              "value": "Jan De Witte"
            },
            {
              "key": "Position",
              "value": "President and Chief Executive Officer"
            },
            {
              "key": "Date",
              "value": "February 22, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 184,
          "title": "Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002",
          "data": [
            {
              "key": "Officer Name",
              "value": "Jan De Witte"
            },
            {
              "key": "Position",
              "value": "President and Chief Executive Officer"
            },
            {
              "key": "Company",
              "value": "Integra LifeSciences Holdings Corporation"
            },
            {
              "key": "Report Period",
              "value": "Year ended December 31, 2022"
            },
            {
              "key": "Certification Date",
              "value": "February 22, 2023"
            },
            {
              "key": "Compliance Statement",
              "value": "The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934."
            },
            {
              "key": "Fair Presentation Statement",
              "value": "The information in the Report fairly presents the financial condition and results of operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 185,
          "title": "Certification of Principal Financial Officer",
          "data": [
            {
              "key": "Officer Name",
              "value": "Jeffrey A. Mosebrook"
            },
            {
              "key": "Position",
              "value": "Senior Vice President, Finance"
            },
            {
              "key": "Company",
              "value": "Integra LifeSciences Holdings Corporation"
            },
            {
              "key": "Reporting Period",
              "value": "Year ended December 31, 2022"
            },
            {
              "key": "Certification Date",
              "value": "February 22, 2023"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": false,
      "elements": []
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 7,
          "title": "Product Launches Overview",
          "data": [
            {
              "key": "Cytal and MicroMatrix",
              "value": "Scheduled for Q1 2023 launch in Europe"
            },
            {
              "key": "Cardion Pericardial Patch",
              "value": "Pilot launched to gain clinical experience"
            },
            {
              "key": "Neutus EVD system",
              "value": "Launched in China in June 2022"
            },
            {
              "key": "CereLink ICP Monitor System",
              "value": "Launched in the U.S. and Europe in 2021, with global rollout continuing in 2022"
            },
            {
              "key": "Aurora Surgiscope",
              "value": "Limited clinical launch conducted in Q3 2021"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 34,
          "title": "New Product Introductions and Research and Development Updates",
          "data": [
            {
              "key": "Product Development Efforts",
              "value": "Innovative product development to drive a multi-generational pipeline for key product franchises."
            },
            {
              "key": "Product Launches",
              "value": "Extended laparoscopic tip launched in the U.S. for CUSA Clarity Tissue Ablation System."
            },
            {
              "key": "New Technologies",
              "value": "Incorporating new ultrasonic handpiece and integrated electrosurgical capabilities in the CUSA Clarity platform."
            },
            {
              "key": "International Launches",
              "value": "Launch of DuraGen in Japan as the first collagen xenograft approved for dural substitution."
            },
            {
              "key": "Recent Acquisitions",
              "value": "Acquisition of Arkiss for CerebroFlo EVD catheter technology, and Rebound Therapeutics for Aurora Surgiscope."
            },
            {
              "key": "Clinical Initiatives",
              "value": "Limited clinical launch of the Aurora Surgiscope and registry MIRROR for data collection."
            },
            {
              "key": "Growth Initiatives",
              "value": "Launch of Aurora Evacuator with Coagulation device in the U.S."
            },
            {
              "key": "Market Expansion",
              "value": "Launch of Neutus EVD system in China."
            },
            {
              "key": "ICP Monitor Launch",
              "value": "CereLink ICP Monitor System launched in the U.S. and Europe."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 67,
          "title": "Property, Plant and Equipment Details",
          "data": [
            {
              "key": "total_gross_assets_2021",
              "value": "626,577"
            },
            {
              "key": "total_gross_assets_2022",
              "value": "641,031"
            },
            {
              "key": "net_property_plant_and_equipment_2021",
              "value": "311,703"
            },
            {
              "key": "net_property_plant_and_equipment_2022",
              "value": "311,302"
            },
            {
              "key": "depreciation_expense_2022",
              "value": "40.1"
            },
            {
              "key": "depreciation_expense_2021",
              "value": "39.4"
            },
            {
              "key": "depreciation_expense_2020",
              "value": "42.1"
            },
            {
              "key": "capitalized_interest_2022",
              "value": "1.4"
            },
            {
              "key": "capitalized_interest_2021",
              "value": "1.2"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 90,
          "title": "Intangible Assets Breakdown",
          "data": [
            {
              "key": "Total Cost of Intangible Assets",
              "value": "$1,697,532,000"
            },
            {
              "key": "Accumulated Amortization",
              "value": "$570,923,000"
            },
            {
              "key": "Net Value",
              "value": "$1,126,609,000"
            },
            {
              "key": "Largest Component (Completed Technology)",
              "value": "$833,357,000"
            },
            {
              "key": "Indefinite Life Asset",
              "value": "Godman trade name"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 90,
          "title": "Intangible Assets and Accumulated Amortization",
          "data": [
            {
              "key": "Total Cost of Assets",
              "value": "$1,646,892,000"
            },
            {
              "key": "Accumulated Amortization",
              "value": "$501,319,000"
            },
            {
              "key": "Net Value",
              "value": "$1,145,000"
            },
            {
              "key": "Largest Asset Category (Completed Technology)",
              "value": "$1,132,954,000"
            },
            {
              "key": "Indefinite Life Asset",
              "value": "Codman trade name"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 95,
          "title": "Change In Projected Benefit Obligations",
          "data": [
            {
              "key": "Projected benefit obligations, beginning of year",
              "value": "65184"
            },
            {
              "key": "Interest cost",
              "value": "194"
            },
            {
              "key": "Service cost",
              "value": "2419"
            },
            {
              "key": "Actuarial (gain) loss",
              "value": "-14822"
            },
            {
              "key": "Plan amendments",
              "value": "-390"
            },
            {
              "key": "Plan settlements",
              "value": "-20"
            },
            {
              "key": "Employee contribution",
              "value": "999"
            },
            {
              "key": "Premiums paid",
              "value": "-391"
            },
            {
              "key": "Benefit payment",
              "value": "-999"
            },
            {
              "key": "Effect of foreign currency exchange rates",
              "value": "-1810"
            },
            {
              "key": "Projected benefit obligations, end of year",
              "value": "50364"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 95,
          "title": "Change In Plan Assets",
          "data": [
            {
              "key": "Plan assets at fair value, beginning of year",
              "value": "39914"
            },
            {
              "key": "Actual return on plan assets",
              "value": "-2863"
            },
            {
              "key": "Employer contributions",
              "value": "2356"
            },
            {
              "key": "Employee contributions",
              "value": "999"
            },
            {
              "key": "Plan settlements",
              "value": "0"
            },
            {
              "key": "Benefits paid",
              "value": "-998"
            },
            {
              "key": "Premiums paid",
              "value": "-391"
            },
            {
              "key": "Effect of foreign currency exchange rates",
              "value": "-964"
            },
            {
              "key": "Plan assets at fair value, end of year",
              "value": "38053"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 95,
          "title": "Reconciliation Of Funded Status",
          "data": [
            {
              "key": "Fair value of plan assets",
              "value": "38053"
            },
            {
              "key": "Benefit obligations",
              "value": "50364"
            },
            {
              "key": "Unfunded benefit obligations",
              "value": "12311"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 38,
          "title": "Revenue and Gross Margin Overview",
          "data": [
            {
              "key": "Total Revenues 2022",
              "value": "$1,557.7 million"
            },
            {
              "key": "Total Revenues 2021",
              "value": "$1,542.4 million"
            },
            {
              "key": "Increase in Revenues",
              "value": "$15.2 million"
            },
            {
              "key": "Gross Margin 2022",
              "value": "$970.3 million"
            },
            {
              "key": "Gross Margin 2021",
              "value": "$944.6 million"
            },
            {
              "key": "Gross Margin Percentage 2022",
              "value": "62.3%"
            },
            {
              "key": "Gross Margin Percentage 2021",
              "value": "61.2%"
            },
            {
              "key": "Impact of Foreign Currency on Revenues",
              "value": "$37.9 million"
            },
            {
              "key": "Domestic Revenue Increase",
              "value": "$41.6 million"
            },
            {
              "key": "International Revenue Increase",
              "value": "$21.7 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 40,
          "title": "Income Taxes and Revenue Distribution",
          "data": [
            {
              "key": "Effective Income Tax Rate 2022",
              "value": "15.6%"
            },
            {
              "key": "Effective Income Tax Rate 2021",
              "value": "21.2%"
            },
            {
              "key": "Estimated Effective Income Tax Rate 2023",
              "value": "20.7%"
            },
            {
              "key": "Federal Net Operating Loss Carryforwards",
              "value": "$79.5 million"
            },
            {
              "key": "Federal NOL Expiry (2037)",
              "value": "$60.9 million"
            },
            {
              "key": "Federal NOL Indefinite Carryforward",
              "value": "$18.6 million"
            },
            {
              "key": "Foreign NOL Indefinite Carryforward",
              "value": "$16.4 million"
            },
            {
              "key": "State NOL Expiry",
              "value": "2036"
            },
            {
              "key": "Domestic Revenue Increase 2022",
              "value": "$37.3 million"
            },
            {
              "key": "European Sales Decrease 2022",
              "value": "$20.4 million"
            },
            {
              "key": "Asia Pacific Sales Decrease 2022",
              "value": "$5.6 million"
            },
            {
              "key": "Rest of World Revenue Increase 2022",
              "value": "$3.9 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 41,
          "title": "Liquidity and Capital Resources",
          "data": [
            {
              "key": "Working Capital 2022",
              "value": "$840.6 million"
            },
            {
              "key": "Working Capital 2021",
              "value": "$813.7 million"
            },
            {
              "key": "Cash and Cash Equivalents 2022",
              "value": "$456.7 million"
            },
            {
              "key": "Cash and Cash Equivalents 2021",
              "value": "$513.4 million"
            },
            {
              "key": "Cash Held by Non-U.S. Subsidiaries",
              "value": "$229.8 million"
            },
            {
              "key": "Net Cash from Operating Activities 2022",
              "value": "$264,469,000"
            },
            {
              "key": "Net Cash from Operating Activities 2021",
              "value": "$312,427,000"
            },
            {
              "key": "Net Cash Used in Investing Activities 2022",
              "value": "-$58,580,000"
            },
            {
              "key": "Net Cash Used in Investing Activities 2021",
              "value": "-$161,443,000"
            },
            {
              "key": "Net Cash Used in Financing Activities 2022",
              "value": "-$251,953,000"
            },
            {
              "key": "Net Cash Used in Financing Activities 2021",
              "value": "-$98,226,000"
            },
            {
              "key": "Net Increase (Decrease) in Cash 2022",
              "value": "-$56,787,000"
            },
            {
              "key": "Net Increase (Decrease) in Cash 2021",
              "value": "$43,282,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 45,
          "title": "Valuation of Acquired IPR&D and Goodwill",
          "data": [
            {
              "key": "IPR&D Fair Value Approach",
              "value": "The Company uses the income approach to determine the fair value of IPR&D acquired in business combinations."
            },
            {
              "key": "Key Assumptions for Valuation",
              "value": "Estimates of cash flows, discount rates, asset life cycles, and competitive trends."
            },
            {
              "key": "Goodwill Valuation",
              "value": "Goodwill is the excess of cost over the fair value of net assets and is reviewed for impairment annually."
            },
            {
              "key": "Goodwill Amount",
              "value": "The Company had goodwill of $1 billion as of December 31, 2022."
            },
            {
              "key": "Intangible Asset Testing",
              "value": "The Company tests intangible assets annually for impairment in the third quarter."
            },
            {
              "key": "Impairment Testing Method",
              "value": "Both qualitative evaluations and quantitative tests are utilized for impairment assessments."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 48,
          "title": "Interest Rate Swaps Financial Impact",
          "data": [
            {
              "key": "Notional Amounts of Interest Rate Swaps",
              "value": "$1.5 billion"
            },
            {
              "key": "Effective Amounts as of December 31, 2022",
              "value": "$775.0 million"
            },
            {
              "key": "Impact of 100 Basis Points Change in Interest Rates",
              "value": "$1.1 million annualized"
            },
            {
              "key": "Report by",
              "value": "PricewaterhouseCoopers LLP"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 50,
          "title": "Financial Statements Index",
          "data": [
            {
              "key": "Report of Independent Registered Public Accounting Firm",
              "value": "PricewaterhouseCoopers LLP, Florham Park, New Jersey, PCAOB ID# 238000"
            },
            {
              "key": "Consolidated Statements of Operations",
              "value": "for the years ended December 31, 2022, 2021 and 2020"
            },
            {
              "key": "Consolidated Statements of Comprehensive Income",
              "value": "for the years ended December 31, 2022, 2021 and 2020"
            },
            {
              "key": "Consolidated Balance Sheets",
              "value": "as of December 31, 2022 and 2021"
            },
            {
              "key": "Consolidated Statements of Cash Flows",
              "value": "for the years ended December 31, 2022, 2021 and 2020"
            },
            {
              "key": "Consolidated Statements of Changes in Stockholders' Equity",
              "value": "for the years ended December 31, 2022, 2021 and 2020"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 55,
          "title": "Financial Information Overview",
          "data": [
            {
              "key": "Company Name",
              "value": "Integra LifeSciences Holdings Corporation"
            },
            {
              "key": "Report Type",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Fiscal Year Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "Filing Date",
              "value": "February 22, 2023"
            },
            {
              "key": "XBRL Format",
              "value": "Formatted as inline XBRL"
            },
            {
              "key": "Key Financial Statements Included",
              "value": "Consolidated Statements of Operations, Consolidated Statement of Comprehensive Income (Loss), Consolidated Balance Sheets, Parenthetical Data to the Consolidated Balance Sheets, Consolidated Statements of Cash Flows, Consolidated Statements of Changes in Stockholders’ Equity, Notes to Consolidated Financial Statements."
            },
            {
              "key": "Commission File Number",
              "value": "000-26224"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 60,
          "title": "Financial Statement Summary",
          "data": [
            {
              "key": "Total revenue, net",
              "value": "$1,557,666"
            },
            {
              "key": "Cost of goods sold",
              "value": "$587,355"
            },
            {
              "key": "Research and development",
              "value": "$101,193"
            },
            {
              "key": "Selling, general and administrative",
              "value": "$616,316"
            },
            {
              "key": "Operating income",
              "value": "$238,920"
            },
            {
              "key": "Net income",
              "value": "$180,550"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 61,
          "title": "Comprehensive Income Statement",
          "data": [
            {
              "key": "Year 2022 Net Income",
              "value": "180550"
            },
            {
              "key": "Year 2022 Total Comprehensive Income",
              "value": "235970"
            },
            {
              "key": "Year 2021 Net Income",
              "value": "169075"
            },
            {
              "key": "Year 2021 Total Comprehensive Income",
              "value": "197979"
            },
            {
              "key": "Year 2020 Net Income",
              "value": "133892"
            },
            {
              "key": "Year 2020 Total Comprehensive Income",
              "value": "136235"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 62,
          "title": "Balance Sheet",
          "data": [
            {
              "key": "Total assets 2022",
              "value": "3889758"
            },
            {
              "key": "Total assets 2021",
              "value": "3782383"
            },
            {
              "key": "Total liabilities 2022",
              "value": "2085355"
            },
            {
              "key": "Total liabilities 2021",
              "value": "2097579"
            },
            {
              "key": "Total stockholders equity 2022",
              "value": "1804403"
            },
            {
              "key": "Total stockholders equity 2021",
              "value": "1684804"
            },
            {
              "key": "Notable changes",
              "value": "Decrease in cash and equivalents, increase in accounts payable, significant improvement in accumulated other comprehensive income from -$45.2M to +$10.3M. Increased treasury stock holdings indicating share buybacks."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 63,
          "title": "Cash Flow Statement",
          "data": [
            {
              "key": "2022 Net income",
              "value": "$180,550"
            },
            {
              "key": "2021 Net income",
              "value": "$169,075"
            },
            {
              "key": "2020 Net income",
              "value": "$133,892"
            },
            {
              "key": "2022 Depreciation and amortization",
              "value": "$118,299"
            },
            {
              "key": "2021 Depreciation and amortization",
              "value": "$119,836"
            },
            {
              "key": "2020 Depreciation and amortization",
              "value": "$116,031"
            },
            {
              "key": "2022 Deferred income tax (benefit) provision",
              "value": "-$4,585"
            },
            {
              "key": "2021 Deferred income tax (benefit) provision",
              "value": "-$2,755"
            },
            {
              "key": "2020 Deferred income tax (benefit) provision",
              "value": "-$64,138"
            },
            {
              "key": "2022 Net cash provided by operating activities",
              "value": "$264,469"
            },
            {
              "key": "2021 Net cash provided by operating activities",
              "value": "$312,427"
            },
            {
              "key": "2020 Net cash provided by operating activities",
              "value": "$203,832"
            },
            {
              "key": "2022 Net cash used in investing activities",
              "value": "-$58,580"
            },
            {
              "key": "2021 Net cash used in investing activities",
              "value": "-$161,443"
            },
            {
              "key": "2020 Net cash used in investing activities",
              "value": "-$68,073"
            },
            {
              "key": "2022 Net cash (used in) provided by financing activities",
              "value": "-$251,953"
            },
            {
              "key": "2021 Net cash (used in) provided by financing activities",
              "value": "-$98,226"
            },
            {
              "key": "2020 Net cash (used in) provided by financing activities",
              "value": "$121,625"
            },
            {
              "key": "2022 Net increase (decrease) in cash and cash equivalents",
              "value": "-$56,787"
            },
            {
              "key": "2021 Net increase (decrease) in cash and cash equivalents",
              "value": "$43,282"
            },
            {
              "key": "2020 Net increase (decrease) in cash and cash equivalents",
              "value": "$271,255"
            },
            {
              "key": "2022 Cash and cash equivalents at beginning of period",
              "value": "$513,448"
            },
            {
              "key": "2021 Cash and cash equivalents at beginning of period",
              "value": "$470,166"
            },
            {
              "key": "2020 Cash and cash equivalents at beginning of period",
              "value": "$198,911"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 65,
          "title": "Notes to Consolidated Financial Statements",
          "data": [
            {
              "key": "Business Overview",
              "value": "Integra LifeSciences Holdings Corporation is a worldwide leader in medical technology, founded on an engineered collagen technology platform."
            },
            {
              "key": "Corporate Development",
              "value": "The company has expanded its regenerative technology business through global acquisitions and product development."
            },
            {
              "key": "Accounting Principles",
              "value": "Financial statements prepared under GAAP, conforming to Regulation S-X."
            },
            {
              "key": "Consolidation Policy",
              "value": "Includes fully owned subsidiaries, with intercompany transactions eliminated."
            },
            {
              "key": "Estimates and Assumptions",
              "value": "Management must make estimates affecting assets and liabilities, contingent liabilities, and revenues."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Future estimates may be affected by the pandemic and economic conditions."
            },
            {
              "key": "Cash Equivalents",
              "value": "Short-term, highly liquid investments with maturities of three months or less."
            },
            {
              "key": "Trade Receivables",
              "value": "Recorded at invoiced amount with evaluations for doubtful accounts based on historical experience."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 70,
          "title": "Notes to Consolidated Financial Statements",
          "data": [
            {
              "key": "Foreign Currency Transaction Net Losses",
              "value": "$3.3 million, net gains of less than $0.1 million, and net losses $1.6 million for the years 2022, 2021, and 2020, respectively."
            },
            {
              "key": "Income Tax Accounting Method",
              "value": "Asset and liability method."
            },
            {
              "key": "Deferred Tax Assets and Liabilities",
              "value": "Recognized for estimated future tax consequences."
            },
            {
              "key": "Tax Position Recognition Threshold",
              "value": "More likely than not to be sustained upon examination."
            },
            {
              "key": "Tax Reserve Classification",
              "value": "Long-term liabilities unless expected to be paid in cash during the next twelve months."
            },
            {
              "key": "Interest and Penalties on Tax Benefits",
              "value": "Classified as a component of income tax expense."
            },
            {
              "key": "Reinvestment of Foreign Earnings",
              "value": "Indefinitely reinvested unless there is a way to remit without material tax cost."
            },
            {
              "key": "Revenue Recognition Principle",
              "value": "Recognized upon the transfer of control of promised products or services."
            },
            {
              "key": "Revenue Components",
              "value": "Product sales, product royalties, and other revenues."
            },
            {
              "key": "Recognition on FOB Shipping Point",
              "value": "Control of product passes to the customer at shipment."
            },
            {
              "key": "Private Label Product Revenue Recognition",
              "value": "Recognized over the manufacturing period, typically one to three months."
            },
            {
              "key": "Control of Consigned Inventory",
              "value": "Retained until the product is used or implanted."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 73,
          "title": "Notes to Consolidated Financial Statements",
          "data": [
            {
              "key": "Adjustment",
              "value": "Deferred tax impact of cumulative-effect adjustment"
            },
            {
              "key": "Consolidated Balance Sheet Classification",
              "value": "Deferred tax liabilities"
            },
            {
              "key": "Amount (in millions)",
              "value": "-20.6"
            },
            {
              "key": "Adjustment",
              "value": "Debt discount reclassification"
            },
            {
              "key": "Consolidated Balance Sheet Classification",
              "value": "Long-term convertible securities"
            },
            {
              "key": "Amount (in millions)",
              "value": "89.1"
            },
            {
              "key": "Adjustment",
              "value": "Equity issuance costs reclassification"
            },
            {
              "key": "Consolidated Balance Sheet Classification",
              "value": "Long-term convertible securities"
            },
            {
              "key": "Amount (in millions)",
              "value": "-2.5"
            },
            {
              "key": "Adjustment",
              "value": "Debt discount amortization and equity costs reclassification, net of tax"
            },
            {
              "key": "Consolidated Balance Sheet Classification",
              "value": "Retained Earnings"
            },
            {
              "key": "Amount (in millions)",
              "value": "-2.8"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 74,
          "title": "Notes to Consolidated Financial Statements",
          "data": [
            {
              "key": "Effective Date of ASU 2021-04",
              "value": "Fiscal years beginning after December 15, 2021, with early adoption permitted."
            },
            {
              "key": "Cash paid for interest (2022)",
              "value": "$42.2 million"
            },
            {
              "key": "Cash paid for interest (2021)",
              "value": "$43.2 million"
            },
            {
              "key": "Cash paid for interest (2020)",
              "value": "$47.3 million"
            },
            {
              "key": "Cash paid for income taxes (2022)",
              "value": "$35.9 million"
            },
            {
              "key": "Cash paid for income taxes (2021)",
              "value": "$49.5 million"
            },
            {
              "key": "Cash paid for income taxes (2020)",
              "value": "$29.8 million"
            },
            {
              "key": "Property and equipment purchases included in liabilities (2022)",
              "value": "$10.5 million"
            },
            {
              "key": "Property and equipment purchases included in liabilities (2021)",
              "value": "$4.7 million"
            },
            {
              "key": "Property and equipment purchases included in liabilities (2020)",
              "value": "$1.6 million"
            },
            {
              "key": "Obligation to former shareholders of Rebound (triggered in 2021)",
              "value": "$5.0 million"
            },
            {
              "key": "Obligation to former shareholders of Rebound (triggered in 2020)",
              "value": "$20.0 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 75,
          "title": "Contract Asset and Liability Statement",
          "data": [
            {
              "key": "Contract asset, January 1, 2022 Transferred to trade receivable from contract asset included",
              "value": "11412"
            },
            {
              "key": "in beginning of the year contract asset",
              "value": "-11412"
            },
            {
              "key": "Contract asset, net of transferred to trade receivables on contracts during the period",
              "value": "10122"
            },
            {
              "key": "Contract asset, December 31, 2022",
              "value": "10122"
            },
            {
              "key": "Contract liability, January 1, 2022",
              "value": "11946"
            },
            {
              "key": "Recognition of revenue included in beginning of year contract liability",
              "value": "-5349"
            },
            {
              "key": "Contract liability, net of revenue recognized on contracts during the period",
              "value": "9596"
            },
            {
              "key": "Foreign currency translation",
              "value": "-66"
            },
            {
              "key": "Contract liability, December 31, 2022",
              "value": "16127"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 83,
          "title": "Notes to Consolidated Financial Statements",
          "data": [
            {
              "key": "Date of First Supplemental Indenture",
              "value": "December 9, 2020"
            },
            {
              "key": "Agreeing Party",
              "value": "Citibank, N.A."
            },
            {
              "key": "2025 Notes Principal Amount",
              "value": "$575.0 million"
            },
            {
              "key": "Fair Value of 2025 Notes (Dec 31, 2022)",
              "value": "$560.5 million"
            },
            {
              "key": "Cash Interest for 2025 Notes (2022, 2021)",
              "value": "$2.9 million"
            },
            {
              "key": "Outstanding Borrowings under Securitization Facility (Dec 31, 2022)",
              "value": "$104.7 million"
            },
            {
              "key": "Weighted Average Interest Rate (2022)",
              "value": "5.0%"
            },
            {
              "key": "Weighted Average Interest Rate (2021)",
              "value": "1.1%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 84,
          "title": "USD LIBOR Loan Details and Fair Value Analysis",
          "data": [
            {
              "key": "Total Notional Amount (2021)",
              "value": "$1,775,000"
            },
            {
              "key": "Total Notional Amount (2022)",
              "value": "$1,475,000"
            },
            {
              "key": "Net Fair Value (2021)",
              "value": "-$43,956"
            },
            {
              "key": "Net Fair Value (2022)",
              "value": "+ $56,712"
            },
            {
              "key": "Fixed Interest Rates Range",
              "value": "1.404% to 3.220%"
            },
            {
              "key": "Loan Termination Range",
              "value": "2024-2027"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 86,
          "title": "Notes to Consolidated Financial Statements",
          "data": [
            {
              "key": "Swap Type",
              "value": "Pay EUR/Receive U.S.$"
            },
            {
              "key": "Effective Date",
              "value": "October 3, 2018"
            },
            {
              "key": "Termination Date",
              "value": "September 30"
            },
            {
              "key": "Fixed Rates",
              "value": "—%, 2.57%"
            },
            {
              "key": "Notional Amount (Currency)",
              "value": "EUR"
            },
            {
              "key": "Notional Amount (Amount)",
              "value": "51,760"
            },
            {
              "key": "Notional Amount (USD Equivalent)",
              "value": "60,000"
            },
            {
              "key": "Fair Value (Asset)",
              "value": "4,713"
            },
            {
              "key": "Fair Value (Liability)",
              "value": "2,503"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 86,
          "title": "Currency Swaps Details",
          "data": [
            {
              "key": "Total Fair Value (Liability)",
              "value": "5,643"
            },
            {
              "key": "Total Fair Value (Asset)",
              "value": "3,858"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 87,
          "title": "Derivatives Designated as Hedges - Balance Sheet Summary",
          "data": [
            {
              "key": "Total derivative assets 2022",
              "value": "$76,173k"
            },
            {
              "key": "Total derivative assets 2021",
              "value": "$16,497k"
            },
            {
              "key": "Total derivative liabilities 2022",
              "value": "$32,874k"
            },
            {
              "key": "Total derivative liabilities 2021",
              "value": "$64,838k"
            },
            {
              "key": "Notional amounts - Interest rate swaps 2022",
              "value": "$1.5 billion"
            },
            {
              "key": "Notional amounts - Interest rate swaps 2021",
              "value": "$1.8 billion"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 89,
          "title": "Foreign Currency Contracts Comparison",
          "data": [
            {
              "key": "Foreign currency forward contracts (2022)",
              "value": "0"
            },
            {
              "key": "Foreign currency forward contracts (2021)",
              "value": "-174"
            },
            {
              "key": "Foreign currency swaps (2022)",
              "value": "1,258"
            },
            {
              "key": "Foreign currency swaps (2021)",
              "value": "62"
            },
            {
              "key": "Total (2022)",
              "value": "1,258"
            },
            {
              "key": "Total (2021)",
              "value": "455"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 89,
          "title": "Goodwill Changes 2021-2022",
          "data": [
            {
              "key": "Goodwill at January 1, 2021",
              "value": "932,367"
            },
            {
              "key": "ACell Acquisition",
              "value": "94,147"
            },
            {
              "key": "Foreign currency translation (2021)",
              "value": "-13,056"
            },
            {
              "key": "Balance at December 31, 2021",
              "value": "1,013,458"
            },
            {
              "key": "Sale of non-core traditional wound care business",
              "value": "-5,019"
            },
            {
              "key": "SIA Acquisition",
              "value": "41,855"
            },
            {
              "key": "Foreign currency translation (2022)",
              "value": "-11,413"
            },
            {
              "key": "Balance at December 31, 2022",
              "value": "1,038,881"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 94,
          "title": "RETIREMENT BENEFIT PLANS DEFINED BENEFIT PLANS",
          "data": [
            {
              "key": "Service cost 2022",
              "value": "2419"
            },
            {
              "key": "Service cost 2021",
              "value": "2741"
            },
            {
              "key": "Interest cost 2022",
              "value": "194"
            },
            {
              "key": "Interest cost 2021",
              "value": "100"
            },
            {
              "key": "Expected return on plan assets 2022",
              "value": "-1381"
            },
            {
              "key": "Expected return on plan assets 2021",
              "value": "-893"
            },
            {
              "key": "Amortization of prior service cost (credit) 2022",
              "value": "-326"
            },
            {
              "key": "Amortization of prior service cost (credit) 2021",
              "value": "-281"
            },
            {
              "key": "Recognized actuarial losses 2022",
              "value": "9"
            },
            {
              "key": "Recognized actuarial losses 2021",
              "value": "186"
            },
            {
              "key": "Settlements 2022",
              "value": "0"
            },
            {
              "key": "Settlements 2021",
              "value": "51"
            },
            {
              "key": "Net period benefit cost 2022",
              "value": "915"
            },
            {
              "key": "Net period benefit cost 2021",
              "value": "1904"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 94,
          "title": "Weighted Average Assumptions",
          "data": [
            {
              "key": "Discount rate 2022",
              "value": "2.44%"
            },
            {
              "key": "Expected return on plan assets 2022",
              "value": "3.61%"
            },
            {
              "key": "Discount rate 2021",
              "value": "0.37%"
            },
            {
              "key": "Expected return on plan assets 2021",
              "value": "3.59%"
            },
            {
              "key": "Rate of compensation increase 2022",
              "value": "1.97%"
            },
            {
              "key": "Rate of compensation increase 2021",
              "value": "2.10%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 97,
          "title": "ROU Assets and Lease Liabilities Comparison",
          "data": [
            {
              "key": "ROU assets (2022)",
              "value": "148,284"
            },
            {
              "key": "ROU assets (2021)",
              "value": "84,543"
            },
            {
              "key": "Current lease liabilities (2022)",
              "value": "14,624"
            },
            {
              "key": "Current lease liabilities (2021)",
              "value": "14,775"
            },
            {
              "key": "Non-current lease liabilities (2022)",
              "value": "157,420"
            },
            {
              "key": "Non-current lease liabilities (2021)",
              "value": "90,329"
            },
            {
              "key": "Total lease liabilities (2022)",
              "value": "172,044"
            },
            {
              "key": "Total lease liabilities (2021)",
              "value": "105,104"
            },
            {
              "key": "Leased facilities term (2022)",
              "value": "16.9 years"
            },
            {
              "key": "Leased facilities term (2021)",
              "value": "10.4 years"
            },
            {
              "key": "Leased vehicles term (2022)",
              "value": "2.0 years"
            },
            {
              "key": "Leased vehicles term (2021)",
              "value": "2.1 years"
            },
            {
              "key": "Leased facilities discount rate (2022)",
              "value": "5.4%"
            },
            {
              "key": "Leased facilities discount rate (2021)",
              "value": "5.1%"
            },
            {
              "key": "Leased vehicles discount rate (2022)",
              "value": "2.7%"
            },
            {
              "key": "Leased vehicles discount rate (2021)",
              "value": "2.6%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 97,
          "title": "Supplemental Cash Flow Information Related to Leases",
          "data": [
            {
              "key": "Operating cash flows from operating leases (2022)",
              "value": "17,442"
            },
            {
              "key": "Operating cash flows from operating leases (2021)",
              "value": "15,077"
            },
            {
              "key": "ROU assets obtained in exchange for lease liabilities (2022)",
              "value": "72,169"
            },
            {
              "key": "ROU assets obtained in exchange for lease liabilities (2021)",
              "value": "12,610"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 97,
          "title": "Lease Payment Schedule and Liability Breakdown",
          "data": [
            {
              "key": "Year 2023 minimum lease payments",
              "value": "20,320"
            },
            {
              "key": "Year 2024 minimum lease payments",
              "value": "21,165"
            },
            {
              "key": "Year 2025 minimum lease payments",
              "value": "19,494"
            },
            {
              "key": "Year 2026 minimum lease payments",
              "value": "17,126"
            },
            {
              "key": "Year 2027 minimum lease payments",
              "value": "16,182"
            },
            {
              "key": "Total minimum lease payments",
              "value": "259,451"
            },
            {
              "key": "Less: Imputed interest",
              "value": "87,407"
            },
            {
              "key": "Total lease liabilities",
              "value": "172,044"
            },
            {
              "key": "Less: Current lease liabilities",
              "value": "14,624"
            },
            {
              "key": "Long-term lease liabilities",
              "value": "157,420"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 98,
          "title": "Operations Revenue Comparison",
          "data": [
            {
              "key": "United States operations 2022",
              "value": "92642"
            },
            {
              "key": "United States operations 2021",
              "value": "91150"
            },
            {
              "key": "United States operations 2020",
              "value": "15082"
            },
            {
              "key": "Foreign operations 2022",
              "value": "121252"
            },
            {
              "key": "Foreign operations 2021",
              "value": "123527"
            },
            {
              "key": "Foreign operations 2020",
              "value": "78438"
            },
            {
              "key": "Total 2022",
              "value": "213894"
            },
            {
              "key": "Total 2021",
              "value": "214677"
            },
            {
              "key": "Total 2020",
              "value": "93520"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 98,
          "title": "Federal Statutory Rate and Tax Reconciliation",
          "data": [
            {
              "key": "Federal statutory rate 2022",
              "value": "21.0%"
            },
            {
              "key": "Federal statutory rate 2021",
              "value": "21.0%"
            },
            {
              "key": "Federal statutory rate 2020",
              "value": "21.0%"
            },
            {
              "key": "State income taxes, net of federal tax benefit 2022",
              "value": "0.1%"
            },
            {
              "key": "State income taxes, net of federal tax benefit 2021",
              "value": "1.9%"
            },
            {
              "key": "State income taxes, net of federal tax benefit 2020",
              "value": "1.2%"
            },
            {
              "key": "Foreign operations 2022",
              "value": "(3.9)%"
            },
            {
              "key": "Foreign operations 2021",
              "value": "(4.0)%"
            },
            {
              "key": "Foreign operations 2020",
              "value": "(7.9)%"
            },
            {
              "key": "Excess tax benefits from stock compensation 2022",
              "value": "(2.4)%"
            },
            {
              "key": "Excess tax benefits from stock compensation 2021",
              "value": "(1.2)%"
            },
            {
              "key": "Excess tax benefits from stock compensation 2020",
              "value": "(1.0)%"
            },
            {
              "key": "Intercompany profit in inventory 2022",
              "value": "0.3%"
            },
            {
              "key": "Intercompany profit in inventory 2021",
              "value": "(0.2)%"
            },
            {
              "key": "Intercompany profit in inventory 2020",
              "value": "1.2%"
            },
            {
              "key": "Nondeductible facilitative costs 2022",
              "value": "0.2%"
            },
            {
              "key": "Nondeductible facilitative costs 2021",
              "value": "0.3%"
            },
            {
              "key": "Nondeductible facilitative costs 2020",
              "value": "1.1%"
            },
            {
              "key": "Contingent Consideration 2022",
              "value": "(2.0)%"
            },
            {
              "key": "Contingent Consideration 2021",
              "value": "(0.2)%"
            },
            {
              "key": "Contingent Consideration 2020",
              "value": "0.2%"
            },
            {
              "key": "Research and development credit 2022",
              "value": "(1.4)%"
            },
            {
              "key": "Research and development credit 2021",
              "value": "(1.2)%"
            },
            {
              "key": "Research and development credit 2020",
              "value": "(1.6)%"
            },
            {
              "key": "Return to provision 2022",
              "value": "(0.5)%"
            },
            {
              "key": "Return to provision 2021",
              "value": "(0.7)%"
            },
            {
              "key": "Return to provision 2020",
              "value": "(2.3)%"
            },
            {
              "key": "Global intangible low-taxed income (GILTI) 2022",
              "value": "2.8%"
            },
            {
              "key": "Global intangible low-taxed income (GILTI) 2021",
              "value": "0.7%"
            },
            {
              "key": "Global intangible low-taxed income (GILTI) 2020",
              "value": "2.5%"
            },
            {
              "key": "Nondeductible executive compensation 2022",
              "value": "1.8%"
            },
            {
              "key": "Nondeductible executive compensation 2021",
              "value": "0.9%"
            },
            {
              "key": "Nondeductible executive compensation 2020",
              "value": "2.4%"
            },
            {
              "key": "Fair market value step up on intra-entity transfer of intellectual property 2022",
              "value": "0%"
            },
            {
              "key": "Fair market value step up on intra-entity transfer of intellectual property 2021",
              "value": "0%"
            },
            {
              "key": "Fair market value step up on intra-entity transfer of intellectual property 2020",
              "value": "(63.3)%"
            },
            {
              "key": "Gain from sale of business - book to tax differences 2022",
              "value": "0%"
            },
            {
              "key": "Gain from sale of business - book to tax differences 2021",
              "value": "3.9%"
            },
            {
              "key": "Gain from sale of business - book to tax differences 2020",
              "value": "2.8%"
            },
            {
              "key": "Other 2022",
              "value": "(0.4)%"
            },
            {
              "key": "Other 2021",
              "value": "0%"
            },
            {
              "key": "Other 2020",
              "value": "0.5%"
            },
            {
              "key": "Effective tax rate 2022",
              "value": "15.6%"
            },
            {
              "key": "Effective tax rate 2021",
              "value": "21.2%"
            },
            {
              "key": "Effective tax rate 2020",
              "value": "(43.2)%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 99,
          "title": "Income Tax Provisions Breakdown",
          "data": [
            {
              "key": "Federal (Current) 2022",
              "value": "24201"
            },
            {
              "key": "Federal (Current) 2021",
              "value": "31938"
            },
            {
              "key": "Federal (Current) 2020",
              "value": "6184"
            },
            {
              "key": "State (Current) 2022",
              "value": "3835"
            },
            {
              "key": "State (Current) 2021",
              "value": "11377"
            },
            {
              "key": "State (Current) 2020",
              "value": "5029"
            },
            {
              "key": "Foreign (Current) 2022",
              "value": "9893"
            },
            {
              "key": "Foreign (Current) 2021",
              "value": "5042"
            },
            {
              "key": "Foreign (Current) 2020",
              "value": "12553"
            },
            {
              "key": "Total current 2022",
              "value": "37929"
            },
            {
              "key": "Total current 2021",
              "value": "48357"
            },
            {
              "key": "Total current 2020",
              "value": "23766"
            },
            {
              "key": "Federal (Deferred) 2022",
              "value": "-11591"
            },
            {
              "key": "Federal (Deferred) 2021",
              "value": "-12830"
            },
            {
              "key": "Federal (Deferred) 2020",
              "value": "-5079"
            },
            {
              "key": "State (Deferred) 2022",
              "value": "-2316"
            },
            {
              "key": "State (Deferred) 2021",
              "value": "-3688"
            },
            {
              "key": "State (Deferred) 2020",
              "value": "-1760"
            },
            {
              "key": "Foreign (Deferred) 2022",
              "value": "9322"
            },
            {
              "key": "Foreign (Deferred) 2021",
              "value": "13763"
            },
            {
              "key": "Foreign (Deferred) 2020",
              "value": "-57299"
            },
            {
              "key": "Total deferred 2022",
              "value": "-4585"
            },
            {
              "key": "Total deferred 2021",
              "value": "-2755"
            },
            {
              "key": "Total deferred 2020",
              "value": "-64138"
            },
            {
              "key": "Provision for income taxes 2022",
              "value": "33344"
            },
            {
              "key": "Provision for income taxes 2021",
              "value": "45602"
            },
            {
              "key": "Provision for income taxes 2020",
              "value": "-40372"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 102,
          "title": "Basic and Diluted Net Income Per Share Analysis",
          "data": [
            {
              "key": "Net income 2022",
              "value": "180,550"
            },
            {
              "key": "Net income 2021",
              "value": "169,075"
            },
            {
              "key": "Net income 2020",
              "value": "133,892"
            },
            {
              "key": "Weighted average common shares outstanding 2022",
              "value": "82,997"
            },
            {
              "key": "Weighted average common shares outstanding 2021",
              "value": "84,698"
            },
            {
              "key": "Weighted average common shares outstanding 2020",
              "value": "84,650"
            },
            {
              "key": "Basic net income per common share 2022",
              "value": "2.18"
            },
            {
              "key": "Basic net income per common share 2021",
              "value": "2.00"
            },
            {
              "key": "Basic net income per common share 2020",
              "value": "1.58"
            },
            {
              "key": "Diluted net income per common share 2022",
              "value": "2.16"
            },
            {
              "key": "Diluted net income per common share 2021",
              "value": "1.98"
            },
            {
              "key": "Diluted net income per common share 2020",
              "value": "1.57"
            },
            {
              "key": "Net income (diluted) 2022",
              "value": "180,550"
            },
            {
              "key": "Net income (diluted) 2021",
              "value": "169,075"
            },
            {
              "key": "Net income (diluted) 2020",
              "value": "133,892"
            },
            {
              "key": "Stock options and restricted stock 2022",
              "value": "519"
            },
            {
              "key": "Stock options and restricted stock 2021",
              "value": "787"
            },
            {
              "key": "Stock options and restricted stock 2020",
              "value": "577"
            },
            {
              "key": "Weighted average common shares for diluted earnings per share 2022",
              "value": "83,516"
            },
            {
              "key": "Weighted average common shares for diluted earnings per share 2021",
              "value": "85,485"
            },
            {
              "key": "Weighted average common shares for diluted earnings per share 2020",
              "value": "85,228"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 102,
          "title": "Comprehensive Income Statement Components (Dollars in thousands)",
          "data": [
            {
              "key": "Balance at December 31, 2021 total",
              "value": "(45,155)"
            },
            {
              "key": "Balance at December 31, 2021 losses from derivatives",
              "value": "(42,981)"
            },
            {
              "key": "Balance at December 31, 2021 defined benefit pension",
              "value": "1,893"
            },
            {
              "key": "Balance at December 31, 2021 foreign currency",
              "value": "(4,067)"
            },
            {
              "key": "Other comprehensive gain (loss) total",
              "value": "69,957"
            },
            {
              "key": "Other comprehensive gain (loss) losses from derivatives",
              "value": "80,335"
            },
            {
              "key": "Other comprehensive gain (loss) defined benefit pension",
              "value": "7,429"
            },
            {
              "key": "Other comprehensive gain (loss) foreign currency",
              "value": "(17,807)"
            },
            {
              "key": "Less: Amounts reclassified from accumulated other comprehensive income total",
              "value": "14,537"
            },
            {
              "key": "Less: Amounts reclassified from accumulated other comprehensive income losses from derivatives",
              "value": "14,537"
            },
            {
              "key": "Net current-period other comprehensive gain (loss) total",
              "value": "55,420"
            },
            {
              "key": "Net current-period other comprehensive gain (loss) losses from derivatives",
              "value": "65,798"
            },
            {
              "key": "Net current-period other comprehensive gain (loss) defined benefit pension",
              "value": "7,429"
            },
            {
              "key": "Net current-period other comprehensive gain (loss) foreign currency",
              "value": "(17,807)"
            },
            {
              "key": "Balance at December 31, 2022 total",
              "value": "10,265"
            },
            {
              "key": "Balance at December 31, 2022 losses from derivatives",
              "value": "22,817"
            },
            {
              "key": "Balance at December 31, 2022 defined benefit pension",
              "value": "9,322"
            },
            {
              "key": "Balance at December 31, 2022 foreign currency",
              "value": "(21,874)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 104,
          "title": "Segment Net Sales and Profit Analysis",
          "data": [
            {
              "key": "Codman Specialty Surgical (2022)",
              "value": ""
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 105,
          "title": "Regional Revenue and Long-lived Assets",
          "data": [
            {
              "key": "2022 Total revenue, net",
              "value": "1,557,666"
            },
            {
              "key": "2021 Total revenue, net",
              "value": "1,542,448"
            },
            {
              "key": "2020 Total revenue, net",
              "value": "1,371,868"
            },
            {
              "key": "2022 Total long-lived assets",
              "value": "516,776"
            },
            {
              "key": "2021 Total long-lived assets",
              "value": "412,686"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 181,
          "title": "Consent of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Report Date",
              "value": "February 22, 2023"
            },
            {
              "key": "Accounting Firm",
              "value": "PricewaterhouseCoopers LLP"
            },
            {
              "key": "Location",
              "value": "Florham Park, New Jersey"
            },
            {
              "key": "Reference",
              "value": "Registration Statements on Form S-8 (Nos. 333-231709, 333-221210, 333-216212, 333-170210, 333-155263, 333-127488, 333-109042, 333-261744 and 333-266353)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 183,
          "title": "Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002",
          "data": [
            {
              "key": "Name",
              "value": "Jeffrey A. Mosebrook"
            },
            {
              "key": "Role",
              "value": "Senior Vice President, Finance"
            },
            {
              "key": "Date",
              "value": "February 22, 2023"
            },
            {
              "key": "Certification Summary",
              "value": "The financial statements and other financial information presented in the report fairly present the financial condition and cash flows."
            },
            {
              "key": "Disclosure Controls set up",
              "value": "Established to ensure material information is known to executives."
            },
            {
              "key": "Evaluation of Controls",
              "value": "Evaluated effectiveness of disclosure controls and procedures."
            },
            {
              "key": "Significant deficiencies",
              "value": "Disclosures made regarding material weaknesses and fraud."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": true,
      "elements": [
        {
          "type": "dividend_policy",
          "page": 58,
          "title": "Report of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Financial Statements",
              "value": "Consolidated balance sheets as of December 31, 2022 and 2021"
            },
            {
              "key": "Internal Control",
              "value": "Effective internal control over financial reporting as of December 31, 2022"
            },
            {
              "key": "Change in Accounting Principle",
              "value": "Accounting for convertible instruments changed in 2021"
            },
            {
              "key": "Audit Findings",
              "value": "No material misstatement found in audited financials"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "dividend_policy",
          "page": 69,
          "title": "Contributions to the Integra Foundation",
          "data": [
            {
              "key": "Company contributions",
              "value": "$0.0 million, $1.2 million and $0.8 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "dividend_policy",
          "page": 69,
          "title": "Testing for Impairment",
          "data": [
            {
              "key": "Asset impairment testing",
              "value": "Annually during the third quarter."
            },
            {
              "key": "Tests for impairment",
              "value": "Qualitative evaluation or quantitative test."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "dividend_policy",
          "page": 127,
          "title": "Description of the Company’s Common Stock",
          "data": [
            {
              "key": "Authorized Shares",
              "value": "The Company’s authorized capital stock consists of 255,000,000 shares of stock, of which 240,000,000 shares are designated as common stock, par value $0.01 per share, and 15,000,000 shares are designated as preferred stock, no par value."
            },
            {
              "key": "Outstanding Shares",
              "value": "As of December 31, 2022, we had 90,476,671 shares of common stock outstanding, 6,822,864 shares were designated as treasury stock, and no shares of preferred stock outstanding."
            },
            {
              "key": "Dividends",
              "value": "Holders of outstanding shares of common stock are entitled to receive dividends out of assets legally available, subject to preferences that may apply to shares of preferred stock outstanding. The ability to pay dividends is limited by the Company’s senior credit facility."
            },
            {
              "key": "Dividends Discretion",
              "value": "Any future determinations to pay cash dividends on our common stock will be at the discretion of the board of directors and depend on financial condition, results of operations, cash flows and other factors."
            },
            {
              "key": "Voting Rights",
              "value": "Each stockholder is entitled to one vote for each share held, without cumulative voting rights. Directors are elected annually."
            },
            {
              "key": "Liquidation Rights",
              "value": "Upon liquidation, holders of common stock would share ratably in distributions after all liabilities and preferred stock preferences are satisfied."
            },
            {
              "key": "Stock Exchange",
              "value": "The common stock is traded on the Nasdaq Global Select Market under the symbol 'IART'."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_share_buyback_plans": {
      "value": true,
      "elements": [
        {
          "type": "share_buyback",
          "page": 31,
          "title": "Share Buyback Programs",
          "data": [
            {
              "key": "2022 ASR Amount",
              "value": "$125.0 million"
            },
            {
              "key": "2022 ASR Shares Received",
              "value": "1.48 million shares"
            },
            {
              "key": "2022 ASR Additional Shares Received",
              "value": "0.46 million shares"
            },
            {
              "key": "2022 ASR Settlement Date",
              "value": "March 24, 2022"
            },
            {
              "key": "2022 ASR Early Exercise Date",
              "value": "March 24, 2022"
            },
            {
              "key": "2022 ASR Total Expected Shares",
              "value": "Unknown"
            },
            {
              "key": "2024 Expiration of Repurchase Authorization",
              "value": "December 2024"
            },
            {
              "key": "Previous Repurchase Authorization Amount",
              "value": "$225 million"
            },
            {
              "key": "Amount Remaining from Previous Authorization",
              "value": "$100 million"
            },
            {
              "key": "2023 ASR Amount",
              "value": "$150 million"
            },
            {
              "key": "2023 ASR Shares Received",
              "value": "2.1 million shares"
            },
            {
              "key": "2023 ASR Completion Expectation",
              "value": "First half of 2023"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "share_buyback",
          "page": 32,
          "title": "Share Repurchase Authorization",
          "data": [
            {
              "key": "Shares Repurchased",
              "value": "None"
            },
            {
              "key": "Details",
              "value": "Further information on share repurchase authorization in Note 8, Treasury Stock."
            },
            {
              "key": "Comparison of 5 Year Cumulative Return",
              "value": "Graph showing cumulative return of IART vs S&P indices."
            },
            {
              "key": "Graph Metadata",
              "value": "Y-axis labeled as 'Value in USD', includes IART and S&P indices as legend items."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "share_buyback",
          "page": 91,
          "title": "Treasury Stock",
          "data": [
            {
              "key": "Shares of treasury stock (2022)",
              "value": "6.8 million"
            },
            {
              "key": "Cost of treasury stock (2022)",
              "value": "$362.9 million"
            },
            {
              "key": "Shares of treasury stock (2021)",
              "value": "4.9 million"
            },
            {
              "key": "Cost of treasury stock (2021)",
              "value": "$234.4 million"
            },
            {
              "key": "Weighted average cost per share (2022)",
              "value": "$53.18"
            },
            {
              "key": "Weighted average cost per share (2021)",
              "value": "$47.86"
            },
            {
              "key": "2023 ASR amount",
              "value": "$150 million"
            },
            {
              "key": "2023 ASR shares received",
              "value": "2.1 million"
            },
            {
              "key": "Total authorized stock repurchase (2022/2024)",
              "value": "$225 million"
            },
            {
              "key": "Remaining authorization from previous program",
              "value": "$100 million"
            },
            {
              "key": "2022 ASR amount",
              "value": "$125 million"
            },
            {
              "key": "2022 ASR shares received",
              "value": "1.48 million"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 53,
          "title": "Anderson Offer Summary",
          "data": [
            {
              "key": "Effective Date",
              "value": "June 24, 2019"
            },
            {
              "key": "Agreement Type",
              "value": "Receivables Financing Agreement"
            },
            {
              "key": "Date of Agreement",
              "value": "December 21, 2018"
            },
            {
              "key": "Involved Parties",
              "value": "Integra Receivables LLC, Integra LifeSciences Sales LLC, PNC Bank, National Association, PNC Capital Markets LLC"
            },
            {
              "key": "Agreement Amendment",
              "value": "Amendment No. 1"
            },
            {
              "key": "Amendment Date",
              "value": "March 29, 2019"
            },
            {
              "key": "Further Amendments",
              "value": "Amendments No. 2, 3, and Purchase and Sale Agreement ongoing"
            },
            {
              "key": "Credit Agreement Date",
              "value": "February 3, 2020"
            },
            {
              "key": "Amendment Date 2",
              "value": "July 14, 2020"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 64,
          "title": "Statement of Changes in Stockholders' Equity",
          "data": [
            {
              "key": "Date (January 1, 2020)",
              "value": "Common Stock Shares: 88735, Common Stock Amount: 887, Treasury Shares: -2865, Additional Paid-in Capital: 1213620, Retained Earnings: 398574, Total Equity: 1416736"
            },
            {
              "key": "Date (December 31, 2020)",
              "value": "Common Stock Shares: 89251, Common Stock Amount: 893, Treasury Shares: -4914, Additional Paid-in Capital: 1290908, Retained Earnings: 532266, Total Equity: 1514867"
            },
            {
              "key": "Date (December 31, 2021)",
              "value": "Common Stock Shares: 89600, Common Stock Amount: 896, Treasury Shares: -4899, Additional Paid-in Capital: 1264943, Retained Earnings: 698568, Total Equity: 1684804"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 82,
          "title": "INTEGRA LIFESCIENCES HOLDINGS CORPORATION Notes to Consolidated Financial Statements - Capital Structure Analysis",
          "data": [
            {
              "key": "Convertible Senior Notes Principal Amount",
              "value": "$575.0 million"
            },
            {
              "key": "Convertible Senior Notes Interest Rate",
              "value": "0.5% per annum"
            },
            {
              "key": "Convertible Senior Notes Maturity",
              "value": "August 15, 2025"
            },
            {
              "key": "Debt Proceeds Classified as Equity",
              "value": "$104.5 million"
            },
            {
              "key": "Effective Interest Rate",
              "value": "4.2%"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 8,
          "title": "Risk Factors Regarding Supply Chain and Regulation",
          "data": [
            {
              "key": "Supply Chain Considerations",
              "value": "Certain components and raw materials are available only from a sole supplier."
            },
            {
              "key": "Regulatory Authorities",
              "value": "Subject to extensive regulation by the FDA and other federal and state authorities."
            },
            {
              "key": "BSE Risk Assessment",
              "value": "Deep flexor tendon and fetal bovine skin are in the lowest-risk category for BSE transmission."
            },
            {
              "key": "Intellectual Property Strategy",
              "value": "We rely upon trade secrets and technological innovations along with patent and trademark protection."
            },
            {
              "key": "Market Trends",
              "value": "Fourth quarter revenues tend to be stronger due to hospital purchasing cycles."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 13,
          "title": "Risk Factors - Compliance with Data Privacy and Cybersecurity Laws",
          "data": [
            {
              "key": "Description",
              "value": "We are subject to requirements relating to information technology which could adversely affect our business."
            },
            {
              "key": "Impact",
              "value": "Complications in business practices, operations, and management requirements."
            },
            {
              "key": "Clinical Research Impact",
              "value": "May complicate clinical research activities and product offerings involving clinical data."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 13,
          "title": "Workforce Demographics",
          "data": [
            {
              "key": "Total Employees",
              "value": "3,722"
            },
            {
              "key": "Contingent Partners",
              "value": "874"
            },
            {
              "key": "Employee Distribution",
              "value": "70% in the United States, 21% in Europe, 2% in Latin America and Canada, 7% in Asia Pacific."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 13,
          "title": "Diversity and Inclusion Commitment",
          "data": [
            {
              "key": "Leadership Engagement",
              "value": "Executive leadership sets diversity and inclusion goals annually."
            },
            {
              "key": "Women’s Leadership Council",
              "value": "Established in 2017, chaired by Jan De Witte."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 17,
          "title": "Risk Factors",
          "data": [
            {
              "key": "Financial Performance",
              "value": "Concerns regarding future financial performance, including financing plans and competition impact."
            },
            {
              "key": "Product Demand",
              "value": "Anticipated demand for products, particularly capital equipment."
            },
            {
              "key": "Production Ability",
              "value": "Ability to produce and deliver products to meet sales demands."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Failure to comply with regulations related to quality standards could adversely affect financial condition."
            },
            {
              "key": "Financing",
              "value": "Ability to obtain additional debt and equity financing for capital expenditures and working capital."
            },
            {
              "key": "Adoption and Reimbursement",
              "value": "Physicians' willingness to adopt products and third-party payors' reimbursement."
            },
            {
              "key": "Intellectual Property",
              "value": "Ability to protect intellectual property and trade secrets."
            },
            {
              "key": "Acquisition Integration",
              "value": "Ability to complete acquisitions and maintain customer relationships post-acquisition."
            },
            {
              "key": "FDA Compliance",
              "value": "Ability to remediate matters identified in FDA observations."
            },
            {
              "key": "Economic Uncertainty",
              "value": "Impact of global economic conditions on operations."
            },
            {
              "key": "Supply Chain Issues",
              "value": "Impact of COVID-19 on global supply chain and costs."
            },
            {
              "key": "Market Demand",
              "value": "Potential decreased demand due to economic uncertainty."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 18,
          "title": "Impact of COVID-19 on Operations and Supply Chain Risks",
          "data": [
            {
              "key": "Risk Description",
              "value": "Exposure to risks associated with public health crises, including epidemics and pandemics such as COVID-19, causing significant volatility and uncertainty in global economies."
            },
            {
              "key": "Impact on Supply Chain",
              "value": "Disruptions in the global supply chain primarily through a lack of availability of raw materials and components, leading to longer shipping times and increased costs."
            },
            {
              "key": "Challenges Faced",
              "value": "Challenges associated with material and component availability, logistics capacity, skilled labor availability, and increased costs across various sectors."
            },
            {
              "key": "Economic Recovery Pace",
              "value": "Uneven recovery pace due to direct and indirect disruptions caused by the pandemic and responses from governments and individuals."
            },
            {
              "key": "Operating Results Fluctuation",
              "value": "Potential fluctuations in operating results that could affect stock price due to various economic factors and disruptions."
            },
            {
              "key": "Factors Causing Fluctuation",
              "value": "Economic conditions, impact of acquisitions, integration challenges, competition, timing of customer orders, changes in market acceptance, retention of employees, regulatory approvals, exchange rates, and operational disruptions due to natural events."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 21,
          "title": "Risks related to acquisitions and product market acceptance",
          "data": [
            {
              "key": "Acquisition Risks",
              "value": "Potential inability to identify suitable acquisition candidates, obtain financing or consummate acquisitions. Antitrust laws impacting acquisition strategy."
            },
            {
              "key": "Financial Performance Impact",
              "value": "Failure in acquisition strategy could adversely impact financial performance."
            },
            {
              "key": "Integration Challenges",
              "value": "Unanticipated costs in business integration could affect earnings."
            },
            {
              "key": "Goodwill and Impairment Tests",
              "value": "Annual testing of goodwill and intangible assets for impairment, risks associated with market changes."
            },
            {
              "key": "Market Acceptance Risks",
              "value": "Dependence on market acceptance of products and competition with established technologies."
            },
            {
              "key": "Reimbursement Challenges",
              "value": "Unfavorable reimbursement decisions may impact product acceptance."
            },
            {
              "key": "Industry Changes",
              "value": "Continuous changes in healthcare due to consolidation, technological improvements, and reform."
            },
            {
              "key": "Product Development Risks",
              "value": "High costs and competition in developing and commercializing new products."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 27,
          "title": "Risks Related to Tax and Debt Obligations",
          "data": [
            {
              "key": "Tax Risks",
              "value": "Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company's operating results."
            },
            {
              "key": "Debt Risks",
              "value": "Our leverage and debt service obligations could adversely affect our business, making it more difficult to satisfy financial obligations."
            },
            {
              "key": " LIBOR Replacement",
              "value": "Changes in the calculation and complete replacement of LIBOR could impact our business, with potential higher interest costs."
            },
            {
              "key": "Intellectual Property Risks",
              "value": "Our intellectual property rights may not provide meaningful commercial protection, enabling third parties to use our technology."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 28,
          "title": "Risks Related to Intellectual Property and Global Operations",
          "data": [
            {
              "key": "Intellectual Property Risks",
              "value": "Our success will depend partly on our ability to operate without infringing or misappropriating the proprietary rights of others."
            },
            {
              "key": "Litigation Risks",
              "value": "We may be involved in lawsuits relating to our intellectual property rights and promotional practices, which may be expensive."
            },
            {
              "key": "Global Operations Risks",
              "value": "If any of our facilities or those of our suppliers were damaged, we could experience lost revenues and our business could be seriously harmed."
            },
            {
              "key": "Insurance Limitations",
              "value": "Our insurance might not cover all losses and we may not be able to renew or obtain such insurance on acceptable terms."
            },
            {
              "key": "Climate Change Impact",
              "value": "Climate change may increase the frequency and severity of extreme weather conditions and natural disasters."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 29,
          "title": "Currency Exchange Risk and Regulatory Challenges",
          "data": [
            {
              "key": "Currency Exchange Risks",
              "value": "Currency exchange risk due to operations in multiple foreign currencies, significant risks with currencies like AUD, GBP, CAD, CNY, EUR, JPY, and CHF."
            },
            {
              "key": "Impact of Laws and Regulations",
              "value": "Subject to laws regarding transactions in sanctioned countries, customs, U.S. Foreign Corrupt Practices Act, and product registration requirements."
            },
            {
              "key": "Geopolitical Risks",
              "value": "Russia-Ukraine conflict creating barriers and impacting global supply chains, monitoring impacts of sanctions."
            },
            {
              "key": "Brexit Effects",
              "value": "Brexit causing uncertainty in regulatory environments, potential restrictions on imports/exports, and currency volatility."
            },
            {
              "key": "Trade Policy Changes",
              "value": "U.S. government changes to trade policies impacting tariffs and trade agreements with countries like China."
            },
            {
              "key": "Cybersecurity Risks",
              "value": "Cyber-attacks disrupting information technology systems could adversely affect business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 66,
          "title": "Account Balance Changes and Adjustments",
          "data": [
            {
              "key": "Provision for doubtful accounts (charges) 2022",
              "value": "$0.2 million"
            },
            {
              "key": "Provision for doubtful accounts (recoveries) 2022",
              "value": "$1.1 million"
            },
            {
              "key": "Provision for doubtful accounts (charges) 2021",
              "value": "$3.6 million"
            },
            {
              "key": "Total deductions",
              "value": "Ranges from -$669,000 to -$1,499,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 66,
          "title": "Inventory Breakdown",
          "data": [
            {
              "key": "Total inventories, net 2022",
              "value": "$324,583,000"
            },
            {
              "key": "Total inventories, net 2021",
              "value": "$317,386,000"
            },
            {
              "key": "Increase in total inventory between 2021 and 2022",
              "value": "2.3%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 88,
          "title": "Hedge Accounting Summary for Years Ended December 31, 2022 and 2021",
          "data": [
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Type",
              "value": "Cash Flow Hedges"
            },
            {
              "key": "Instrument",
              "value": "Interest rate swap"
            },
            {
              "key": "Beginning Balance",
              "value": "-43956"
            },
            {
              "key": "Gain/Loss Recognized",
              "value": "93308"
            },
            {
              "key": "Gain/Loss Reclassified",
              "value": "-7360"
            },
            {
              "key": "Ending Balance",
              "value": "56712"
            },
            {
              "key": "Location",
              "value": "Interest expense"
            },
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Type",
              "value": "Cash Flow Hedges"
            },
            {
              "key": "Instrument",
              "value": "Cross-currency swap"
            },
            {
              "key": "Beginning Balance",
              "value": "-9688"
            },
            {
              "key": "Gain/Loss Recognized",
              "value": "8847"
            },
            {
              "key": "Gain/Loss Reclassified",
              "value": "19430"
            },
            {
              "key": "Ending Balance",
              "value": "-20271"
            },
            {
              "key": "Location",
              "value": "Other income, net"
            },
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Type",
              "value": "Net Investment Hedges"
            },
            {
              "key": "Instrument",
              "value": "Cross-currency swap"
            },
            {
              "key": "Beginning Balance",
              "value": "-2321"
            },
            {
              "key": "Gain/Loss Recognized",
              "value": "2196"
            },
            {
              "key": "Gain/Loss Reclassified",
              "value": "6789"
            },
            {
              "key": "Ending Balance",
              "value": "-6914"
            },
            {
              "key": "Location",
              "value": "Interest income"
            },
            {
              "key": "Year",
              "value": "Total"
            },
            {
              "key": "Beginning Balance",
              "value": "-55965"
            },
            {
              "key": "Gain/Loss Recognized",
              "value": "104351"
            },
            {
              "key": "Gain/Loss Reclassified",
              "value": "18859"
            },
            {
              "key": "Ending Balance",
              "value": "29527"
            },
            {
              "key": "Year",
              "value": "2021"
            },
            {
              "key": "Type",
              "value": "Cash Flow Hedges"
            },
            {
              "key": "Instrument",
              "value": "Interest rate swap"
            },
            {
              "key": "Beginning Balance",
              "value": "-93769"
            },
            {
              "key": "Gain/Loss Recognized",
              "value": "27402"
            },
            {
              "key": "Gain/Loss Reclassified",
              "value": "-22411"
            },
            {
              "key": "Ending Balance",
              "value": "-43956"
            },
            {
              "key": "Location",
              "value": "Interest expense"
            },
            {
              "key": "Year",
              "value": "2021"
            },
            {
              "key": "Type",
              "value": "Cash Flow Hedges"
            },
            {
              "key": "Instrument",
              "value": "Cross-currency swap"
            },
            {
              "key": "Beginning Balance",
              "value": "-1073"
            },
            {
              "key": "Gain/Loss Recognized",
              "value": "24275"
            },
            {
              "key": "Gain/Loss Reclassified",
              "value": "32890"
            },
            {
              "key": "Ending Balance",
              "value": "-9688"
            },
            {
              "key": "Location",
              "value": "Other income, net"
            },
            {
              "key": "Year",
              "value": "2021"
            },
            {
              "key": "Type",
              "value": "Net Investment Hedges"
            },
            {
              "key": "Instrument",
              "value": "Cross-currency swap"
            },
            {
              "key": "Beginning Balance",
              "value": "-12291"
            },
            {
              "key": "Gain/Loss Recognized",
              "value": "16515"
            },
            {
              "key": "Gain/Loss Reclassified",
              "value": "6545"
            },
            {
              "key": "Ending Balance",
              "value": "-2321"
            },
            {
              "key": "Location",
              "value": "Interest income"
            },
            {
              "key": "Year",
              "value": "Total"
            },
            {
              "key": "Beginning Balance",
              "value": "-107133"
            },
            {
              "key": "Gain/Loss Recognized",
              "value": "68192"
            },
            {
              "key": "Gain/Loss Reclassified",
              "value": "17024"
            },
            {
              "key": "Ending Balance",
              "value": "-55965"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 16,
          "title": "Employee Health and Safety and Engagement Updates",
          "data": [
            {
              "key": "Employee Development Programs",
              "value": "Integra recommends external job-specific development programs for employees."
            },
            {
              "key": "Health and Safety Commitment",
              "value": "Integra is committed to providing a safe environment and implements health and safety management systems."
            },
            {
              "key": "COVID-19 Response",
              "value": "Measures for employee safety during the COVID-19 pandemic include hygiene practices and PPE."
            },
            {
              "key": "Employee Engagement Surveys",
              "value": "Conduct bi-annual surveys to gauge employee sentiment and engagement."
            },
            {
              "key": "Wellbeing Programs",
              "value": "Programs include health insurance, disability coverage, and wellness initiatives."
            },
            {
              "key": "Financial Information Availability",
              "value": "Financial statements and SEC filings can be accessed online."
            },
            {
              "key": "Forward-Looking Statements",
              "value": "Statements regarding future expectations subject to risks and uncertainties."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 19,
          "title": "Impact of Changes to Sales Organization and Regulatory Environment",
          "data": [
            {
              "key": "Impact of Sales Organization Changes",
              "value": "Changes to sales organization and channel expansion, including increased specialization."
            },
            {
              "key": "Clinical Effectiveness Publications",
              "value": "Peer-reviewed publications discussing the clinical effectiveness of products."
            },
            {
              "key": "Manufacturing Compliance Inspections",
              "value": "Inspections of manufacturing facilities for compliance, possibly resulting in adverse findings."
            },
            {
              "key": "Regulatory Changes Impact",
              "value": "Changes in regulations impacting sales and marketing practices."
            },
            {
              "key": "Increased Regulatory Scrutiny",
              "value": "Scrutiny of products could lead to removal from market or corrective actions."
            },
            {
              "key": "Intellectual Property Enforcement",
              "value": "Enforcement or defense of intellectual property rights."
            },
            {
              "key": "Tax Law Changes",
              "value": "Changes in tax laws or interpretations could affect financial performance."
            },
            {
              "key": "Goodwill and Intangible Asset Impairment",
              "value": "Impact of impairment charges in case of poor operating results of acquired businesses."
            },
            {
              "key": "Competitive Landscape",
              "value": "Description of the highly competitive environment within the medical device industry."
            },
            {
              "key": "Competition with Established Companies",
              "value": "Competes with established medical technology companies and early-stage firms."
            },
            {
              "key": "Pricing and Market Share Competition",
              "value": "Need to compete on price due to intense competition and managed care environment."
            },
            {
              "key": "Impact of Healthcare Trends",
              "value": "Changes in healthcare industry could reduce product prices and market size."
            },
            {
              "key": "Third-Party Payer Standards",
              "value": "Annual revisions by payors affecting reimbursement methodologies."
            },
            {
              "key": "International Healthcare Reforms",
              "value": "Foreign country reforms to reduce spending through effective procedures."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 39,
          "title": "Non-operating Income and Expense Statement",
          "data": [
            {
              "key": "interest income",
              "value": "$11,917"
            },
            {
              "key": "Interest expense",
              "value": "-$49,594"
            },
            {
              "key": "Gain from sale of business",
              "value": "$644"
            },
            {
              "key": "Other income, net",
              "value": "$12,007"
            },
            {
              "key": "Total non-operating income and expense",
              "value": "-$25,026"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 46,
          "title": "Income Taxes and Market Risk Exposure",
          "data": [
            {
              "key": "Identifiable Intangible Assets",
              "value": "$1.1 billion"
            },
            {
              "key": "Effective Tax Rate",
              "value": "Depends on geographic distribution of pre-tax earnings"
            },
            {
              "key": "Tax Law Changes",
              "value": "Affects profits and reserve for uncertain tax benefits"
            },
            {
              "key": "Foreign Earnings",
              "value": "Indefinitely reinvested unless remitted with no material tax cost"
            },
            {
              "key": "Market Risks",
              "value": "Includes changes in foreign currency exchange rates and interest rates"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 49,
          "title": "Evaluation of Controls and Procedures",
          "data": [
            {
              "key": "Effective Controls Evaluation Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Internal Control Over Financial Reporting Evaluation Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Changes in Internal Control",
              "value": "No changes that materially affected controls during the quarter ended December 31, 2022."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 68,
          "title": "Goodwill and Other Intangible Assets",
          "data": [
            {
              "key": "Key Subject",
              "value": "Fair value of acquired intangible assets"
            },
            {
              "key": "Methodology",
              "value": "Determines fair values based on detailed valuations"
            },
            {
              "key": "Goodwill",
              "value": "Recorded as excess of cost over fair value of net assets"
            },
            {
              "key": "Impairment Review",
              "value": "Reviewed annually or if indicators arise"
            },
            {
              "key": "Segments",
              "value": "Two reportable segments with three reporting units"
            },
            {
              "key": "Other Intangibles",
              "value": "Includes patents, trademarks, purchased technology, customer relationships"
            },
            {
              "key": "Uncertainty",
              "value": "Risks associated with achieving commercialization of projects"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 100,
          "title": "Deferred Tax Assets and Liabilities",
          "data": [
            {
              "key": "Doubtful accounts",
              "value": "2261"
            },
            {
              "key": "Inventory related items",
              "value": "31950"
            },
            {
              "key": "Tax credits",
              "value": "13084"
            },
            {
              "key": "Accrued vacation",
              "value": "2175"
            },
            {
              "key": "Accrued bonus",
              "value": "4944"
            },
            {
              "key": "Stock compensation",
              "value": "10175"
            },
            {
              "key": "Deferred revenue",
              "value": "2130"
            },
            {
              "key": "Net operating loss carryforwards",
              "value": "30707"
            },
            {
              "key": "Capitalization of research and development expenses",
              "value": "51542"
            },
            {
              "key": "Unrealized foreign exchange gain",
              "value": "6228"
            },
            {
              "key": "Charitable contributions carryforward",
              "value": "180"
            },
            {
              "key": "Leases and Other",
              "value": "39788"
            },
            {
              "key": "Total deferred tax assets",
              "value": "195164"
            },
            {
              "key": "Less valuation allowance",
              "value": "-9651"
            },
            {
              "key": "Deferred tax assets after valuation allowance",
              "value": "185513"
            },
            {
              "key": "Intangible and fixed assets",
              "value": "-166891"
            },
            {
              "key": "Unrealized foreign exchange loss",
              "value": "-12991"
            },
            {
              "key": "Leases and Other",
              "value": "-22975"
            },
            {
              "key": "Total deferred tax liabilities",
              "value": "-202857"
            },
            {
              "key": "Total net deferred tax assets (liabilities)",
              "value": "-17344"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 101,
          "title": "Deferred Tax Assets Valuation Allowance Analysis",
          "data": [
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Description",
              "value": "Deferred tax assets valuation allowance"
            },
            {
              "key": "Balance at Beginning of Period",
              "value": "15258"
            },
            {
              "key": "Charged to Costs and Expenses",
              "value": "-515"
            },
            {
              "key": "Deductions",
              "value": "-71"
            },
            {
              "key": "Balance at End of Period",
              "value": "14672"
            },
            {
              "key": "Year",
              "value": "2021"
            },
            {
              "key": "Balance at Beginning of Period",
              "value": "13825"
            },
            {
              "key": "Charged to Costs and Expenses",
              "value": "1444"
            },
            {
              "key": "Other",
              "value": "89"
            },
            {
              "key": "Deductions",
              "value": "-100"
            },
            {
              "key": "Balance at End of Period",
              "value": "15258"
            },
            {
              "key": "Year",
              "value": "2020"
            },
            {
              "key": "Balance at Beginning of Period",
              "value": "N/A"
            },
            {
              "key": "Charged to Costs and Expenses",
              "value": "N/A"
            },
            {
              "key": "Other",
              "value": "N/A"
            },
            {
              "key": "Deductions",
              "value": "N/A"
            },
            {
              "key": "Balance at End of Period",
              "value": "N/A"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 101,
          "title": "Tax Position Balance Reconciliation",
          "data": [
            {
              "key": "Period",
              "value": "Balance, beginning of year"
            },
            {
              "key": "2022",
              "value": "676"
            },
            {
              "key": "2021",
              "value": "702"
            },
            {
              "key": "2020",
              "value": "676"
            },
            {
              "key": "Period",
              "value": "Gross increases: Current year tax positions"
            },
            {
              "key": "2022",
              "value": "37"
            },
            {
              "key": "2021",
              "value": "0"
            },
            {
              "key": "2020",
              "value": "0"
            },
            {
              "key": "Period",
              "value": "Prior years' tax positions"
            },
            {
              "key": "2022",
              "value": "0"
            },
            {
              "key": "2021",
              "value": "0"
            },
            {
              "key": "2020",
              "value": "26"
            },
            {
              "key": "Period",
              "value": "Other"
            },
            {
              "key": "2022",
              "value": "0"
            },
            {
              "key": "2021",
              "value": "0"
            },
            {
              "key": "2020",
              "value": "0"
            },
            {
              "key": "Period",
              "value": "Balance, end of year"
            },
            {
              "key": "2022",
              "value": "713"
            },
            {
              "key": "2021",
              "value": "676"
            },
            {
              "key": "2020",
              "value": "702"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 110,
          "title": "Section 2.03 - Proposals at Annual Meeting",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Proposing Person Notification Period",
              "value": "Two (2) business days after determining not to proceed with solicitation of proxies."
            },
            {
              "key": "Bylaws Compliance",
              "value": "Proposals must comply with the provisions of these Bylaws and applicable Exchange Act requirements."
            },
            {
              "key": "Disregarded Proposals",
              "value": "Proposals not made in accordance with Bylaws will be disregarded."
            },
            {
              "key": "Qualified Representative Requirement",
              "value": "Must be authorized by a written instrument or electronic transmission."
            },
            {
              "key": "Proxy Requirements",
              "value": "Written instrument or electronic transmission must be produced at the meeting."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 141,
          "title": "Performance Vesting Percentage and Award of Performance Stock",
          "data": [
            {
              "key": "Performance Vesting Percentage",
              "value": "Percentage determined based on achievement of Performance Goals during the Performance Period."
            },
            {
              "key": "Qualifying Termination",
              "value": "Termination of Service by the Company without Cause or by the Participant for Good Reason."
            },
            {
              "key": "Termination of Service",
              "value": "When the Participant ceases to provide services to the Company and its Related Corporations."
            },
            {
              "key": "Vested",
              "value": "Condition that shares of Performance Stock must meet to be considered vested."
            },
            {
              "key": "Dividend Equivalents",
              "value": "Amounts equal to the regular quarterly cash dividend paid to Vested but unissued shares of Performance Stock."
            },
            {
              "key": "Change in Control",
              "value": "Occurs prior to payment of dividend equivalents affecting payment terms."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 171,
          "title": "CHINA Terms and Conditions of Participation in the Plan",
          "data": [
            {
              "key": "Compliance with Law",
              "value": "The Participant acknowledges that the participation is subject to Company obtaining approval from the State Administration of Foreign Exchange."
            },
            {
              "key": "Sale of Shares",
              "value": "The Participant agrees that the Company can sell Shares on the Participant’s behalf to comply with laws and regulations."
            },
            {
              "key": "Termination of Employment",
              "value": "Shares must be sold within sixty days following termination of employment."
            },
            {
              "key": "Exchange Control Restrictions",
              "value": "Shares must be held in a designated broker account and sold through that broker."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 172,
          "title": "Cash Dividends and Reporting Obligations",
          "data": [
            {
              "key": "Cash Dividends",
              "value": "The Participant understands that cash dividends paid on Shares may be transferred to a special exchange control account required by the Company."
            },
            {
              "key": "Currency Risk",
              "value": "The Participant agrees to bear any currency fluctuation risk between the time the Shares are sold or dividends are paid and the time the proceeds are distributed."
            },
            {
              "key": "French Tax Compliance",
              "value": "French residents must declare any cash or securities held outside France and face penalties for non-compliance."
            },
            {
              "key": "German Cross-Border Reporting",
              "value": "The Participant must report cross-border payments over €12,500 to the German Federal Bank."
            },
            {
              "key": "Qualified Participation",
              "value": "Participants must report acquisitions leading to a qualified participation if they exceed €150,000."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 9,
          "title": "FDA Regulations and Compliance for Medical Devices and HCT/Ps",
          "data": [
            {
              "key": "Regulatory Oversight",
              "value": "Products are regulated by the FDA for safety, efficacy, and quality standards."
            },
            {
              "key": "Regulatory Actions",
              "value": "Consequences of non-compliance include fines, penalties, and product recalls."
            },
            {
              "key": "Regulatory Process",
              "value": "The approval process for medical devices can take several years and may involve clinical trials."
            },
            {
              "key": "HCT/P Definition",
              "value": "Human Cells, Tissues, and Cellular and Tissue-Based Products regulated under specific FDA guidelines."
            },
            {
              "key": "AATB Compliance",
              "value": "Accreditation by the American Association of Tissue Banks is necessary for tissue establishments."
            },
            {
              "key": "FDA Guidance Documents",
              "value": "Guidance on minimal manipulation and homologous use was issued by the FDA in July 2020."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 10,
          "title": "FDA Guidance on Medical Devices and Enforcement Actions",
          "data": [
            {
              "key": "HCT/P Final Guidance",
              "value": "The FDA maintains that certain products do not meet criteria for regulation solely as HCT/Ps."
            },
            {
              "key": "Enforcement Discretion",
              "value": "Extended to May 31, 2021, some uses could be subject to immediate enforcement."
            },
            {
              "key": "Manufacturing Discontinuation",
              "value": "The Company discontinued manufacturing certain products before the enforcement deadline."
            },
            {
              "key": "Despite Notices",
              "value": "No further enforcement notice received from the FDA as of December 31, 2022."
            },
            {
              "key": "510(k) Clearance",
              "value": "Required for introducing new medical devices or new indications for existing devices."
            },
            {
              "key": "PMA Process",
              "value": "Reserved for new devices not substantially equivalent to any predicate device."
            },
            {
              "key": "FDA Registration",
              "value": "Manufacturers must register with the FDA and comply with extensive regulations."
            },
            {
              "key": "Quality System Regulations",
              "value": "FDA's requirements for maintaining documents in prescribed manner."
            },
            {
              "key": "Regulatory Compliance Audits",
              "value": "Integra manufacturing facilities audited annually under Medical Device Single Audit Program."
            },
            {
              "key": "European Regulations",
              "value": "Devices must comply with GSPR under EU Medical Devices Regulation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 11,
          "title": "Regulatory Concerns and Compliance",
          "data": [
            {
              "key": "CE Mark Certification",
              "value": "Required for marketing in the EEA, transition to new EU MDR requirements might pose challenges for continuing to market products in the EU."
            },
            {
              "key": "Risk Factors",
              "value": "Subject to stringent domestic and foreign medical device regulations."
            },
            {
              "key": "Postmarket Requirements",
              "value": "Includes FDA Quality System Regulations, reporting for adverse events, and recalls."
            },
            {
              "key": "Anti-Bribery Laws",
              "value": "Subject to U.S. and foreign laws related to healthcare fraud and marketing practices."
            },
            {
              "key": "Import-export Laws",
              "value": "Laws regarding sanctioned countries and restrictions affecting operations."
            },
            {
              "key": "Hazardous Materials Handling",
              "value": "Compliance with environmental and safety laws for hazardous materials used in processes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 12,
          "title": "Regulatory Compliance and Legal Risks",
          "data": [
            {
              "key": "Regulatory Shutdown Liability",
              "value": "Integra may face a regulatory shutdown of a facility impacting product distribution."
            },
            {
              "key": "Compliance Costs",
              "value": "Potential substantial costs to comply with future environmental laws."
            },
            {
              "key": "Employee Health & Safety Compliance",
              "value": "Compliance procedures are essential for business objectives."
            },
            {
              "key": "Third-Party Reimbursement",
              "value": "Healthcare providers rely on third-party payors for product cost coverage."
            },
            {
              "key": "Data Privacy and Cybersecurity Compliance",
              "value": "Compliance with data privacy laws may lead to increased costs and regulatory enforcement."
            },
            {
              "key": "HIPAA Regulations",
              "value": "Obligated to comply with HIPAA for protecting patient health information."
            },
            {
              "key": "GDPR Compliance",
              "value": "Subject to EU GDPR for processing personal data of EU residents."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 23,
          "title": "Risks Related to Our Regulatory Environment",
          "data": [
            {
              "key": "Economic Impact",
              "value": "Economic and political instability could adversely affect hospitals' ability to access funds impacting budgets and production."
            },
            {
              "key": "Regulatory Changes",
              "value": "Health care reforms and government initiatives may adversely impact business and financial outcomes."
            },
            {
              "key": "Legislative Changes",
              "value": "Recent legislation has reduced Medicare and Medicaid payments impacting healthcare providers."
            },
            {
              "key": "FDA Regulations",
              "value": "FDA policies may change affecting product approval and compliance."
            },
            {
              "key": "Market Adaptation",
              "value": "Market stress from regulatory changes may affect customer purchasing decisions."
            },
            {
              "key": "Future Health Reform Measures",
              "value": "Potential future healthcare reforms could change reimbursement dynamics, impacting product demand."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 24,
          "title": "Government Regulation",
          "data": [
            {
              "key": "Regulatory Agencies",
              "value": "Various agencies monitor and enforce compliance with laws and regulations governing medical devices."
            },
            {
              "key": "FDA Approval Process",
              "value": "Obtaining marketing approval from FDA and foreign regulatory agencies is costly and can lead to delays."
            },
            {
              "key": "Consequences of Non-Compliance",
              "value": "Failure to comply with regulations can result in significant enforcement actions, including halting studies and penalties."
            },
            {
              "key": "EU Medical Device Regulation Compliance",
              "value": "Expenditures for compliance amounted to $45.1 million for the year ended December 31, 2022."
            },
            {
              "key": "Chinese Regulatory Environment",
              "value": "The regulatory environment in China is evolving and may impact operations and lead to fines."
            },
            {
              "key": "Healthcare Marketing Regulations",
              "value": "Healthcare companies must comply with regulations like the Anti-Kickback Statute and False Claims Act."
            },
            {
              "key": "AdvaMed Code Compliance",
              "value": "Adopted the AdvaMed Code of Ethics for best practices in interactions with healthcare providers."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 25,
          "title": "Regulatory Compliance Issues",
          "data": [
            {
              "key": "General Data Protection Regulation (GDPR)",
              "value": "Subject to EU regulations regarding personal data."
            },
            {
              "key": "California Consumer Privacy Act (CCPA)",
              "value": "Subject to state laws on privacy in the U.S."
            },
            {
              "key": "China Personal Information Protection Law",
              "value": "Focus on protecting personal information and requires compliance."
            },
            {
              "key": "Consequences of Noncompliance",
              "value": "Fines up to 4% of global annual revenue possible."
            },
            {
              "key": "Regulatory Reporting Requirements",
              "value": "Medical device products subject to additional reporting even post-approval."
            },
            {
              "key": "Bovine and Porcine Tissue Products",
              "value": "Subject to special scrutiny and regulations due to animal origin."
            },
            {
              "key": "BSE Risks",
              "value": "Products derived from animal tissues could face additional regulations."
            },
            {
              "key": "Recall Procedures",
              "value": "FDA powers in enforcing recalls on defective products."
            },
            {
              "key": "Impact of Regulatory Challenges",
              "value": "Delays and failures in compliance may lead to reputational harm and financial losses."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 26,
          "title": "Regulatory Risks and Requirements",
          "data": [
            {
              "key": "Approval for tendon use",
              "value": "Received approval in the U.S., the EU, Japan, Taiwan, China, Argentina."
            },
            {
              "key": "BSE risk and sales prohibition",
              "value": "Potential prohibition on collagen product sales if sourcing from BSE-free countries is disrupted."
            },
            {
              "key": "Environmental Compliance",
              "value": "Subject to environmental laws, which may impose compliance costs."
            },
            {
              "key": "Use of hazardous materials",
              "value": "Controlled use of hazardous materials in manufacturing and R&D."
            },
            {
              "key": "Risk of liability",
              "value": "Potential liability from accidents or contamination related to hazardous materials."
            },
            {
              "key": "Climate change risks",
              "value": "Subject to physical and transition risks related to climate change."
            },
            {
              "key": "IT compliance regulations",
              "value": "Subject to data privacy and cybersecurity laws across jurisdictions."
            },
            {
              "key": "Employee retention challenges",
              "value": "Increasing challenges in recruiting and retaining skilled employees."
            },
            {
              "key": "Tax liabilities",
              "value": "Subject to income taxes and audits, with uncertainties in tax determination."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 85,
          "title": "INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "cross-currency swaps agreements",
              "value": "The Company entered into cross-currency swap agreements to convert a notional amount of $471.6 million equivalent to 420.1 million of a CHF-denominated intercompany loan into U.S. dollars."
            },
            {
              "key": "total fair value liability",
              "value": "The total fair value liability across all swaps ranges from $(7,769) to $(8,242)."
            },
            {
              "key": "foreign exchange risk management",
              "value": "The Company manages certain foreign exchange risks through a variety of strategies, including hedging."
            },
            {
              "key": "finished settlement as of October 3, 2022",
              "value": "The Company settled cross-currency swaps designated as cash flow hedges of an intercompany loan with aggregate notional amounts of $100 million."
            },
            {
              "key": "gain upon settlement",
              "value": "Based on the closing exchange rates, the gain upon settlement of these swaps was approximately $1.6 million."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 123,
          "title": "Indemnification of Directors and Officers",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Indemnification Clause",
              "value": "Any person who was or is a party to any action, suit or proceeding shall be indemnified by the Corporation against expenses, judgments, fines, excise taxes, and amounts paid in settlement."
            },
            {
              "key": "Advances",
              "value": "Expenses incurred in defending any action shall be paid by the Corporation in advance of the final disposition."
            },
            {
              "key": "Procedure",
              "value": "Indemnification or advances shall be made within sixty (60) days upon written request."
            },
            {
              "key": "Defense",
              "value": "The burden of proving the defense rests on the Corporation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 126,
          "title": "Jurisdiction and Severability in Bylaws",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 21, 2023"
            },
            {
              "key": "Exclusive Jurisdiction",
              "value": "Delaware Courts or U.S. Federal District Courts"
            },
            {
              "key": "Scope of Jurisdiction",
              "value": "Derivative actions, breach of fiduciary duty claims, claims against the Corporation or officers/employees"
            },
            {
              "key": "Implications of Invalid Provisions",
              "value": "Remaining provisions remain effective; intent given effect despite invalidity."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 128,
          "title": "Anti-Takeover Effects and Business Combination Provision",
          "data": [
            {
              "key": "Preferred Stock Issuance",
              "value": "The Board of Directors has authority to issue up to 15,000,000 shares of Preferred Stock."
            },
            {
              "key": "Market Impact",
              "value": "Issuing preferred stock could decrease the market price of common stock."
            },
            {
              "key": "Section 203 DGCL",
              "value": "Prevents 15%+ stockholders from business combinations for three years unless certain conditions are met."
            },
            {
              "key": "Stockholder Approval",
              "value": "Business combinations require approval from the Board and/or a supermajority of non-interested stockholders."
            },
            {
              "key": "Bylaws Restrictions",
              "value": "Provisions in bylaws may discourage tender offers and takeover attempts."
            },
            {
              "key": "Special Meetings",
              "value": "May only be called by the chairman, president, or Board."
            },
            {
              "key": "Action by Written Consent",
              "value": "Stockholders can act by written consent with Board's record date setting."
            },
            {
              "key": "Director Vacancies",
              "value": "Filled exclusively by the remaining Board members."
            },
            {
              "key": "Director Removal",
              "value": "Directors can only be removed for cause by a vote of 80% of outstanding stock."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 168,
          "title": "Data Protection Laws and Participant Rights",
          "data": [
            {
              "key": "Data Retention",
              "value": "The Company will use the Participant’s personal data only as long as necessary, generally seven years after participation, ceasing when no longer needed."
            },
            {
              "key": "Rights of the Participant",
              "value": "The Participant may have rights under data privacy laws including access to data, rectification, deletion, restrictions on processing, objection to processing, portability, lodging complaints, and receiving a list of data recipients."
            },
            {
              "key": "Necessary Disclosure",
              "value": "Providing personal data is necessary for contractual obligations related to the Award Agreement."
            },
            {
              "key": "Applicable Laws",
              "value": "The Plan applies to the Income Tax Assessment Act 1997 and complies with the Corporations Act 2001 in Australia."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": false,
      "elements": []
    },
    "has_supply_chain_disruptions": {
      "value": true,
      "elements": [
        {
          "type": "supply_chain_disruption",
          "page": 22,
          "title": "Supply Chain Disruption Risk Factors",
          "data": [
            {
              "key": "Key components and materials",
              "value": "The company's reliance on outside vendors, some of whom are sole-source suppliers, for crucial components and raw materials."
            },
            {
              "key": "Impact of supply interruption",
              "value": "Interruption in supply could harm manufacturing ability until a new or alternative source is identified."
            },
            {
              "key": "Factors affecting products",
              "value": "Collagen-based and bovine-based products, silicone products, specialty parts, biosynthetic products, amniotic and porcine tissue-based products."
            },
            {
              "key": "Sterilization services",
              "value": "Dependence on third-party suppliers for sterilization and potential disruptions from those suppliers."
            },
            {
              "key": "Influencing economic factors",
              "value": "Unanticipated price increases due to economic disruptions, component shortages, inflation, recessionary conditions, and geopolitical events."
            },
            {
              "key": "Inventory policy",
              "value": "Policy is to maintain sufficient inventory to mitigate disruptions."
            },
            {
              "key": "Facility consolidation and manufacturing transfers",
              "value": "Consolidation of facilities could present challenges such as unexpected costs and operational impacts."
            },
            {
              "key": "Product liability exposure",
              "value": "Risk of product liability claims and insurance coverage limitations."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 6,
          "title": "Research and Development Strategy",
          "data": [
            {
              "key": "Overview",
              "value": "The research and development activities focus on identifying unmet surgical needs and addressing those with innovative solutions and products."
            },
            {
              "key": "Core Competency",
              "value": "Apply core competency in regenerative technology to innovate products for neurosurgical, wound applications, plastic surgery, and reconstructive surgery."
            },
            {
              "key": "Budget Allocation",
              "value": "A large portion of the research and development budget is allocated to projects involving regenerative technology."
            },
            {
              "key": "Innovation",
              "value": "Conduct extensive R&D development programs targeting the core platforms of electromechanical technologies."
            },
            {
              "key": "Evidence Generation",
              "value": "Conduct products and clinical studies to generate efficacy and health economic evidence."
            },
            {
              "key": "Market Leadership",
              "value": "Integra is a world leader in regenerative technology and was the first to receive FDA claim for regeneration of dermal tissue."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 14,
          "title": "Diversity and Inclusion Initiatives at Integra",
          "data": [
            {
              "key": "Description",
              "value": "The Council focuses on attracting and retaining female talent, advancing women into leadership roles, increasing cultural awareness of inclusion and diversity, and creating development forums for high-performing women."
            },
            {
              "key": "Executive Leadership Team Sponsorship",
              "value": "Members of the Executive Leadership Team serve as sponsors for Integra’s employee resource groups."
            },
            {
              "key": "Employee Resource Groups",
              "value": "Currently, Integra has six Employee Resources Groups including Women of Integra Networks (WIN), African American Affinity Group, Veteran Employee Resource Group, Indian American Network, Asian American and Pacific Islander Network, and Integra PRIDE."
            },
            {
              "key": "Partnerships",
              "value": "Integra partners with organizations such as CEO Action for Diversity & Inclusion and Healthcare Businesswomen’s Association."
            },
            {
              "key": "Training Programs",
              "value": "Programs include Managing Unconscious Bias and Practicing Inclusion, which are mandatory for all new hires."
            },
            {
              "key": "Gender Diversity Statistics",
              "value": "48% of the overall population is female, 38% of executive leaders and 43% of senior leaders are female."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 30,
          "title": "Cybersecurity Risks and ESG Initiatives",
          "data": [
            {
              "key": "Summary",
              "value": "The document discusses risks associated with cybersecurity threats affecting business operations and the implementation of ESG (Environmental, Social, and Corporate Governance) practices."
            },
            {
              "key": "Cybersecurity Risks",
              "value": "Increased risks due to internet reliance and remote work during COVID-19, potential for data breaches and unauthorized access."
            },
            {
              "key": "ESG Practices",
              "value": "Focus on climate change, sustainability, and corporate governance, including a published inaugural ESG report."
            },
            {
              "key": "Consequences of Poor ESG Compliance",
              "value": "Potential negative impacts on reputation, financial condition, and customer or investor relations if ESG practices fail to meet expectations."
            },
            {
              "key": "Current Status with SEC",
              "value": "No unresolved comments from the SEC as of the filing date."
            },
            {
              "key": "Properties",
              "value": "Leased office space in Princeton, NJ, with a lease expiring in 2035."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 35,
          "title": "FDA Matters regarding product launches and regulatory actions",
          "data": [
            {
              "key": "NeuraGen 3D Nerve Guide Matrix",
              "value": "Launched in 2022 for peripheral nerve repair."
            },
            {
              "key": "PriMatrix Dermal Repair Scaffold",
              "value": "Completed trials for DFU management, enrolled over 225 patients."
            },
            {
              "key": "Integra Bilayer Wound Matrix",
              "value": "Announced positive clinical data on 2020 for complex lower extremity reconstruction."
            },
            {
              "key": "CereLink monitors recall",
              "value": "Global product removal initiated on August 18, 2022 due to out-of-range pressure readings."
            },
            {
              "key": "TEI Biosciences Warning Letter",
              "value": "Received from FDA on March 6, 2019 regarding quality systems issues."
            },
            {
              "key": "2021 FDA Form 483",
              "value": "Issued post-inspection with observations requiring corrective actions."
            },
            {
              "key": "Financial transactions",
              "value": "$1.9 million provision for product returns and $0.8 million rework accrual in 2022."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 180,
          "title": "Company Locations and Incorporations in Medical Sector",
          "data": [
            {
              "key": "company_name",
              "value": "Jarit GmbH"
            },
            {
              "key": "location",
              "value": "Germany"
            },
            {
              "key": "company_name",
              "value": "XU Healthcare, Inc. - Medical Specialty Products"
            },
            {
              "key": "location",
              "value": "Delaware"
            },
            {
              "key": "company_name",
              "value": "MedEfficiency, Inc."
            },
            {
              "key": "location",
              "value": "Delaware"
            },
            {
              "key": "company_name",
              "value": "Minnesota Scientific, Inc."
            },
            {
              "key": "location",
              "value": "Minnesota"
            },
            {
              "key": "company_name",
              "value": "Newdeal SAS"
            },
            {
              "key": "location",
              "value": "France"
            },
            {
              "key": "company_name",
              "value": "Newdeal, Inc."
            },
            {
              "key": "location",
              "value": "Texas"
            },
            {
              "key": "company_name",
              "value": "Precise Dental Holding Corp."
            },
            {
              "key": "location",
              "value": "New Jersey"
            },
            {
              "key": "company_name",
              "value": "Precise Dental Internacional, S.A. de C.V."
            },
            {
              "key": "location",
              "value": "Mexico"
            },
            {
              "key": "company_name",
              "value": "Precise Dental Products, Ltd."
            },
            {
              "key": "location",
              "value": "California"
            },
            {
              "key": "company_name",
              "value": "Precision Dental International, Inc."
            },
            {
              "key": "location",
              "value": "California"
            },
            {
              "key": "company_name",
              "value": "Rebound Therapeutics Corporation"
            },
            {
              "key": "location",
              "value": "Delaware"
            },
            {
              "key": "company_name",
              "value": "Spembly Cryosurgery Limited"
            },
            {
              "key": "location",
              "value": "United Kingdom"
            },
            {
              "key": "company_name",
              "value": "Spembly Medical Limited"
            },
            {
              "key": "location",
              "value": "United Kingdom"
            },
            {
              "key": "company_name",
              "value": "Surgical Innovation Associates, Inc."
            },
            {
              "key": "location",
              "value": "Delaware"
            },
            {
              "key": "company_name",
              "value": "Tarsus Medical Inc."
            },
            {
              "key": "location",
              "value": "Delaware"
            },
            {
              "key": "company_name",
              "value": "TEI Biosciences (UK) Limited"
            },
            {
              "key": "location",
              "value": "United Kingdom"
            },
            {
              "key": "company_name",
              "value": "TEI Biosciences Inc."
            },
            {
              "key": "location",
              "value": "Delaware"
            },
            {
              "key": "company_name",
              "value": "TEI Medical Inc."
            },
            {
              "key": "location",
              "value": "Delaware"
            },
            {
              "key": "company_name",
              "value": "TGX Medical Systems, LLC"
            },
            {
              "key": "location",
              "value": "Delaware"
            }
          ],
          "currency": "USD"
        }
      ]
    }
  },
  "currency": {
    "USD": 96,
    "EUR": 54,
    "GBP": 1,
    "JPY": 1,
    "AUD": 10,
    "CAD": 1,
    "CHF": 1,
    "CNY": 1,
    "ZAR": 11
  },
  "sha1": "f85f0ccbbc59f1423d52d44e5ab70e3a01164499"
}